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PREFACE 
The purpose of this study is the investigation of synthetic routes toward boron-
containing thymidine and uridine analogues that have potential for acting as substrates for 
DNA polymerases to be incorporated into replicating DNA. 
Three methods of investigation were utilized in the search for boron-containing 
thymidine and uridine analogues. The first investigation involved the coupling and 
cyclization of a boronate and a urea. Model studies involving benzylurea were used to 
investigate reaction conditions for the coupling but led to the decomposition and 
rearrangement of the boronate. The second investigation entailed using thiophene as a 
synthetic backbone in the preparation of precursors to thymidine analogues. The trigonal 
boronatomin2-benzyl-1,3-dihydro-1-hydroxythieno[3,2-c][1,5,2]diazaborin-3(2H)-one, the 
thiophene-based precursor, was shown to be stable in a variety of solvent environments. The 
third investigation employed asymmetric synthesis ofboronic esters in the preparation of 
boron-containing acyclic precursors to uracil. This method continues to be investigated for 
its applications in the synthesis of boron-containing nucleoside analogues. 
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CHAPTER ONE 
INTRODUCTION 
Design and Significance of Boron-Containing Nucleoside Analogues 
The projects presented within this document were pursued at Oklahoma State 
University and Washington State University under the direction of Steven Graham and 
Donald Matteson. Though geographically separated, the visions of the advisors for the 
projects were quite similar. The initial goal was to synthesize boron-containing nucleoside 
analogues which have unexplored potential as inhibitors of HIV, as anticancer agents, and 
as tools to study the basic mechanisms of DNA (deoxyribonucleic acid) replication, 
alkylation and repair. 
Because there are differing beliefs about the properties of these molecules, this initial 
discussion will present these beliefs with the understanding that they are merely speculative. 
In addition, the two projects were first presented with different ideas as to the eventual use 
of the boron-containing nudeoside analogues. Therefore, the potential uses of boron-
containing nucleoside analogues will also be discussed in some detail. 
Experimental Background 
Over 40 years ago, Dewar established a class of compounds, designated as borazaro, 
which includes 4-borauracil and 4-borathymine. 1•2 These boron analogues of uracil and 
thymine (Figure 1) are the only analogues expected to have some stability toward water. 
The 2-isomer has two hydrolytically unstable B-N bonds3 making it useless for the 
1 
applications proposed for boron-containing nucleoside analogues. The 5- and 6-isomers are 
not allowed due to valence rules. 
Figure 1. Boron Analogues of Uracil and Thymine. 
OH OH 0 HQ 0 {NH H,~/,,NH ('NH HO,B)lNH r-NH 
N~O N~O l(N~B,._OH -1~ A H-~B~N~O -..;::N 0 H +. +1 H H I H H 
4°borauracil 4-borathymine 2-borauracil 5-borauracil 6-borauracil 
With the predicted stability of 4-borauracil and the similar compound 4-borathymine, 
these two compounds became the targets of the syntheses in the following chapters. In spite 
of the predicted stability of 4-borauracil, several attempts to synthesize this compound by 
different research groups have failed over the last 35 years.4•5 
Figure 2. Reactions of Boron Heterocycles with Base. 
boroxaroquinoline 
OH 
I C(NH I 
N 
OH" 
borazaroquinoline 
2 
Though attempts to prepare 4-borauracil have been unsuccessful, there is some 
precedent for the synthesis of boron-containing heterocycles. Dewar and coworkers 
prepared boroxaroquinoline and borazaroquinoline (Figure 2).2 These two compounds 
react very differently when exposed to hydroxide ion, as evidenced by the 11B NMR 
Boroxaroquinoline reacts with the hydroxide ion at the boron to form the tetracoordinate 
borate but the more aromatic borazaroquinoline loses a proton from the hydroxyl making 
it analogous to phenol (Figure 2).6•7 Groziak et al. later proved that these two analogues 
maintain planar, aromatic structures in aqueous solution using NMR. They were also able 
to demonstrate that hydrogen bonding occurs between borazaroquinoline and a cytidine 
derivative (Figure 3 ). 8 
Figure 3. Hydrogen Bonding Pattern ofBorazaroquinoline and a Cytidine Derivative. 
Groziak and coworkers also synthesized otherbenzo-fused heterocycles and found 
that these compounds tended to hydrate in water.9 Soloway also recently achieved the 
synthesis of benzoborauracil and showed that it is stable in water. To date, benzo-fused 
heterocycles of varying stability (Figure 4)9•11 have been prepared, but the search continues 
for a way to synthesize borauracil or borathymine without the added aromatic support. The 
work presented in the following chapters is simply a continuation of this 35-year old search. 
3 
Figure 4. Structures of Known Benzo-fused Boron Heterocycles. 
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Desired Properties of Boron-Containing Nucleoside Analogues 
Once the boron analogues ofuridine and thymidine are synthesized, the potential for 
these compounds to substantially mimic the natural molecules must be explored. The first 
step would be to study whether or not the nucleosides could become phosphorylated to their 
corresponding nucleotides. The simplest method for predicting phosphorylation is to use 
affinity chromatography, where the interaction of immobilized nucleosides with kinases is 
explored. Even though this technique may be a useful indicator as to whether or not the 
reaction takes place, based on the accessibility and binding of the nucleosides to the active 
sites of the kinases, it may not be a realistic representation of the rate of the reaction. 12 
The second step would be to investigate hydrogen bonding possibilities with natural 
nucleobases using nuclear magnetic resonance. If hydrogen bonding could be shown to 
occur with one of the natural nucleobases in the normal Watson-Crick hydrogen bonding 
pattern, there would be a greater potential for these compounds to be incorporated into 
4 
replicating DNA This property is subject to debate and may be based on the boron 
substitution. Because of the odd valence of boron, borauracil without other substituents is 
not expected to maintain the Watson-Crick type hydrogen bonding. However, it is believed 
that the substitution of an alkyl or electrophilic alkyl group on the borinate may maintain the 
original hydrogen bonding pattern of the normal base (Figure 5). Any of these molecules 
that could be prepared would have potential as a drug for antiviral or anticancer treatment 
or as a chemical probe for studying the mechanisms associated with DNA. 
Figure 5. Proposed Hydrogen Bonding Pattern for the Alkyl Form of Borauridine. 
H3~ 01111 H-NH ....,.. 
...,,.°ti ~N-~"'·~~~Vtb 0yN-i ~N 
I O 0 
I 0-J 
O..; Normal A:T base pair 
For some of the potential uses ofboronacontaining nuc1eoside analogues, it would 
be beneficial for the triphosphates of the boron-containing nucleoside analogues to be used 
by DNA polymerases (E. Coli pol I, Klenow, bacteriophage T4, HIV reverse transcriptase) 
during replication. Preliminary studies to determine whether these compounds act as 
substrates would make use of oligomeric DNA templates annealed to short radiolabeled 
complementary primers. 13 Incubation of the template-primer pair would then be carried out 
in the presence of three of the four natural deoxynucleotides and the analogue (Figure 6). 
Repeating this experiment \\1th all four combinations would provide information as to the 
extent of incorporation into DNA or disruption of DNA synthesis in the presence of the 
5 
analogue. Extension of the growing DNA strand up to and including the missing natural 
nucleotide implies that the analogue is able to mimic the missing nucleotide and establishes 
which base is complementary to the analogue. If extension continues beyond the unique 
nucleotide, it is implied that the analogue does not block DNA synthesis.14,15 
Figure 6. Primer Extension Studies for Analogues with DNA Polymersases. 
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Template 3' A 
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Extended Primer? 
Extended Primer? 
Extended Primer? 
Extended Primer? 
When the original proposals for the research presented here were submitted, 
astonishing statistics had just been released by the Center for Disease Control, causing a stir 
in the research community. In 1995, the announcement that HIV (Human 
Immunodeficiency Virus) was no longer just another epidemic but now the leading cause 
of death for those aged 25-44 in the United States came as a shock. We were unable to 
6 
comprehend how such a disease could rise from non-existence to major killer within a . 
fifteen-year span (Figure 7). 16 Around that same time, continuing research with HIV showed 
Figure 7. AIDS Deaths from 1980 to 1999 in the United States. 
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that the virus does not lie dormant during the apparent latent phase but is continually 
replicating at a rate of more than one billion times per day. 17 These two statements, made 
to the public, renewed the push to find a cure for the newest plague of our society. 
Educators and health care professionals took on the challenge of informing the public as to 
how to help control the transmission of the disease. Scientists began searching for new and 
improved ways to treat and conquer the virus that was plaguing the United States. 
The first cases of AIDS (Acquired Immune Deficiency Syndrome) in the United 
States appeared in five young, previously healthy, homosexually active men in Los Angeles 
in the spring of 1981. These men were first diagnosed with a rare upper respiratory 
infection, Pneumocystis carinii pneumonia, that later became linked to a reduced ability to 
7 
fight off even the simplest infections, such as the common cold. 1&-20 Within one month, 10 
other cases of the same rare infection were identified in addition to 26 cases of Kaposi's 
sarcoma, a rare cancer of the connective and vascular tissue. 21 By December of 1981, there 
had been 257 cases of AIDS identified and reported to the Center for Disease Control. 19•22 
This initial growth statistic seems overwhelming until we look more carefully at the rates 
of infectio~ progression to AIDS, and death within the United States. Only then is the full 
power of the disease unveiled. 
Since the appearance ofHIV in the United States, there has beenanongoingsearch 
to identify the initial mode of infection and rapid transmission of the virus. With the initial 
cases being identified in homosexual males, focus was first placed on this particular 
lifestyle. We now know that the main mode of transmission is through sexual contact, 
whether homosexual or heterosexual. In fact, depending on the part of th~ world being 
considered, these two modes of transmission may be interchanged as the most prevalent 
route of infection (Figure 8).23 
8 
Figure 8. Comparison ofIDV Transmission Routes for the United States and the World: 
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In 1995, a new case of HIV was reported every fifteen seconds, more than 5000 per 
day in the world.24 As if this weren't shocking enough, someone dies from AIDS every 30 
minutes. At that time, an estimated 216,000 people were living with AIDS in the United 
States.25 Though it was thought that the rate of infection would dramatically decrease as a 
result of the educational programs (Figure 9), this trend was not seen in the next five years. 
Due, in part, to a push for people in high risk categories to be tested for HIV, an unexpected 
9 
up-tum in infection was seen rather than a decline during this period. As a result of 
continued infectio~ at the end of 2000 there were an estimated 313,000 people living with 
AIDS in this country alone.26 Obviously, the epidemic is as real today as it was in the 1980s 
when scientists and physicians were first figuring out how to identify HIV I AIDS as anything 
other than the opportunistic diseases that afflict people infected with HIV. 
Figure 9. Annual HIV Infections Reported within the United States from 1993 to 2000. 
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In addition to the fear of becoming infected with HIV, with 313,000 people living 
with HIV/AIDS in the United States, the public health system will soon be stressed beyond 
its available resources at the expense of others in the community. Unfortunately, with the 
cost of medical treatment, infected people will not be able to pay for care out of their own 
resources. The estimate for necessary medical care to protect against opportunistic diseases 
from HIV infection to death is anywhere from $119,000 to 147,000 for one infected 
person.27,28 Of this, half of the expenses ($62,000 to 73,000) are associated with treatment 
10 
from the onset of AIDS to death,27'28 a 12- to 15-month span in most cases. The hope of 
finding a cure is not only for those suffering from HIV I AIDS but for the rest of society. 
Viral Cycle of HIV 
HIV belongs to a group of retroviruses known more specifically as cytopathic 
lentoviruses. Lentoviruses are able to integrate their viral genetic material into a host cell's 
genetic material through reverse transcription. The use of reverse transcription is the one 
feature that distinguished retroviruses from other viruses. Though there are several 
retroviruses known to man, focus has been placed on two main types in recent years. The 
first, Human T-cell Lymphotropic Virus type-I (HTLV-I) and HLTV-II, causes unrestrained 
growth and proliferation of white blood cells, which eventually leads to the onset of 
leukemia. The second, HIV-1 and HIV-2, causes a profound deterioration of the immune 
system by the loss and dysfunction of T-helper lymphocytes. 23 Since these two types of 
viruses share T-helper cells as a common pathogenic target, research leading to the 
suppression of one may be beneficial for the treatment of the other. For this reason, little 
emphasis will be placed on HTL V itself within this document. 
HIV targets the human body at cells of the central nervous system and the immune 
system giving rise to weakened immune defenses. Though lay people in the discussion of 
the plague of our lifetime frequently interchange HIV and AIDS, these two acronyms apply 
to very different stages of the viral cycle. In fact, ,AJDS may never develop as a result of 
HIV infection. Long-term nonprogressors, people who survive with HIV for more than 10 
to 15 years and show no signs of HIV disease, remain a mystery to scientists. Speculations 
as to what protects these individuals range from extraordinary killer T-cells effective against 
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the virus to infection by a weak strain of the virus and even genetics. - In terms of genetics, 
the focus becomes the presence of certain receptors. Binding-of JilV involves the CD4 
molecule and CCR-2, CXCR-4 or CCR-5 coreceptors. Evidence indicates that people who 
inherit two mutated genes for the CCR-5 receptor may be highly resistant to JilV infection 
while those who inherit only one mutated copy tend to be long-term nonprogressors.29 
Upon·infection,·mv seeks to attach itself to T-helper lymphocytes. The virions? 
which look like small balls covered with suction cups (Figure 10),29 use their envelope 
Figure 10. Schematic of a Mature JilV Virion. 
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surface protein, gp 120, to attach to the outside of the membrane encasing the T-helper cells 
at the CD4 (cluster determinant 4) receptor (Figure 1 la). The CD4 receptor is the gate for 
all infectious agents30 and must be_ present for the infection of the T-helper cell by JilV to 
12 
Figure 11. Replication Cycle oflllV from Infection to the Formation of New Virions. 
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occur. Once the virus has entered the host cell, the envelope protein is stripped from the 
virion (Figure l lb) and the viral RNA is transcribed into DNA by reverse transcriptase 
(Figure 11 c ), an enzyme specifically designed to copy RNA into DNA. The new retroviral 
DNA is then integrated into the genetic material of the host cell forming proviral DNA 
(Figure lld).30•31 With this insertion, each time the host cell transcribes its DNA into 
messenger-RNA a new retrovirus (viral mRNA) is also made.23•32 
The newly-transcribed viral mRNA produces the structural proteins, envelope 
proteins, regulatory proteins and RNA necessary for Llie production ofHIV (Figure 1 le ). 19;33 
The new viral RNA is then encapsulated as the core of the newly produced proteins in the 
assembly of new HIV (Figure 11 t). 34.35 Once the assembly of the virion is complete, the 
replicated virus particles bud and are released from the host cell, killing the host cell in the 
process (Figure 11 g). 23,32 
There are many phases that occur with the infection of T-helper cells by HIV. The 
first period is very brief but intense in terms of the amount of viral replication that occurs.36 
During this early period, HIV multiplies and disseminates rapidly causing massive quantities 
of virus (viremia) to be present throughout the body. This phase of mass production is 
followed by a latent phase. It ,vas originally thought that HIV particles were actually 
dormant during this time. In 1995, research by Coffin et al. indicated that the virus was not 
hibernating during this time but hiding within the T-helper cells, inserting its genetic 
material into the host cell's DNA, and constantly 
replicating. 17 The "silent" infection that takes place during this time is not synonymous 
with asymptomatic periods that occur throughout the progression of HIV infection. 37-39 The 
difference between these two states is the detection of the virus by the body's immune 
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system. During the "silent" infection, the body is unable to identify and fight the hidden 
virus, while during asymptomatic periods the body is able to fight the virus just enough for 
the person to seem healthy. 
The dormant HIV particles that have been hidingin the T-cells are triggered by other 
opportunistic viruses, such as herpes simplex, hepatitis B, HTL V, or Epstein-Barr.34.4° The 
attack of these viruses seems to weaken the immune system further and cause the synthesis 
of proteins and assembly of new HIV to be initiated. 20•30 Once the T-helper cell has been 
. ovetwhelmed by the growing virus, the new virus particles bud from the host cell, destroying 
a small piece of the immune system in the process.39•41 The destruction that occurs can 
happen on many levels. The first is the straightforward destruction of the host cell by 
breaking open the outer membrane of the cell. The second occurs when the virus sheds 
fragments of envelope protein gpl20, which then adhere to CD4 surface molecules of 
uninfected, neighboring T-helper cells. This attachment of gp 120 to CD4 receptors causes 
the formation of profoundly damaged cells ( syncytia ), in this case a multinucleated clump 
of functionally incapacitated cells,30•39•42 and the subsequent immune response to destroy 
these otherwise healthy cells.43 The third occurs when unintegrated HIV DNA interferes 
with the fundamental function of T-helper cells. 34 In addition to these specific methods, 
several other means by which HIV destroys cells have been well established.43 
Disrupting Replication 
When a virus is defined, care must be taken to distinguish the status of the virus 
inside a cell from that of the virus outside a cell. Inside the cell, the virus is actively 
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multiplying while on the outside it appears to be merely another chemical. Therefore, 
research targets processes within the cell for the development of antiviral agents. 
As seen previously, there are many steps involved in the replication of HIV. Each 
step along the path could be targeted by antiviral drugs (Figure 12)32 designed to interfere 
with the replication cycle. For example, amantadine, a drug used to treat an influenza A 
infection, prevents the virus from ever entering the host cell. 32· Many antiviral drugs, 
including the herpes drug, acyclovir, interfere with the replication of the nucleic acid. 32 The 
other tnain target for antiviral agents occurs later in the cycle when genetic material of the 
progeny are assembled and released. Interferon, an agent produced by the body, as well as 
synthetically, affects many viruses at this later stage.32 
Theoretically, numerous targets exist for the development of drugs that could be 
selectively active against HIV. Since the hope would be to target a step in the replication 
process that will distinguish the virus from the host cell, reverse transcription has become 
the target of most drug development. Reverse transcription is the ideal process· because this 
step does not occur in the host cells while retroviruses rely on this process for multiplication. 
Therefore, targeting reverse transcription, more specifically the enzyme reverse 
transcriptase, should have little toxicity to host cells. Unfortunately, the drugs currently in 
use all have significant toxicity so the search continues for non-toxic agents. 
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Figure 12. Anti .. viral Drugs Tested Against HIV. 
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DNA Polymerase Inhibition 
One strategy for disrupting replication is the use of a boron-containing nucleoside 
analogue to inhibit DNA polymerases, including HIV reverse transcriptase. This property 
may be independent of the inclusion of boron-containing nucleoside analogues into 
replicating DNA but is tested in a manner similar to that previously described. All four 
natural deo:xynucleotides and the analogue are incubated with the template-primer pair in 
the presence of a DNA polymerase. If the DNA polymerase preferentially incorporates the 
natural deoxynucleotides, incomplete or decelerated extension of the primer implies that the 
boron-containing nucleoside analogue acts as an inhibitor of the polymerase.44 Of course, 
these studies could easily be repeated to determine the kinetic and equilibrium parameters, 
~and kc.it-
Alkylation of DNA 
' 
Alkylation-induced dam11ge of DNA is a common strategy for disrupting replication 
m the treatment of cancer and may be applicable to the treatment of viruses. 45-48 
Unfortunately the alkylating drugs (mitomycin C, nitrogen mustards, nitrosoureas) suffer 
from the inability to distinguish replicating from non-replicating DNA and deactivation of 
the drugs by reaction with non-DNA cellular nucleophiles. 
The damage caused by the inability of the drugs to distinguish a diseased cell from 
a healthy cell has been implicated in mutagenesis within the healthy cell and its progeny.4s..si 
The changes in DNA, as a result of alkylation, are manifested as either alteration of the 
Watson-Crick hydrogen bonding pattern or mutations within the genetic material of the cell. 
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The observed mutation is often the result of continued replication in which a mismatched 
base is incorporatedopposite the alkylated base.50•51 
Mismatched-induced mutagenesis can potentially be avoided in two ways. First, a 
double alkylation may be introduced to fonn an interstrand cross-link that would hinder 
mutations by suppressing the separation of DNA necessary for subsequent replication. A 
cross-link of this sort also makes DNA resistant to denaturation and in vivo repair. Second, 
alkylations that result in the maintenance of the natural hydrogen bonding patterns will be 
less mutagenic if the alkylation does not·lead to an interstrand cross--link.48•52 . 
DNA Cross-linking 
Highly reactive DNA cross-linking agents can be controlled by combining the 
alkylating agent with an oligonucleotide in order to create a site-specific cross-linking 
agent. 14,47•53-59 If the alkylating functionality can be properly placed so as to have a 
complimentary base trigger cross-linking upon hybridization of duplex DNA, reactivity may 
also be modulated. 14•56•57 While these two approaches have been studied and were successful 
in forming site-specific interstrand cross-links, very few investigations have been carried out 
using replicating DNA, implying that little is known about the association of the agents with 
DNA polymerase and the involved kinases. 
A study carried out by Cowart and Benkovic, 14 in which the nucleoside analogue, 
6edDTP (Figure 13), was synthesized and then subjected to various tests, demonstrated the 
potential use of nucleoside analogues in alkylation and cross-linking of DNA. Though the 
synthesis of the aziridine - containing nucleoside triphosphate analogue based on 
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Figure 13. 6ed.DTP was Used to Demonstrate the Potential for Analogues to Alkylate 
and Cross-link DNA 
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deoxyguanosine triphosphate was not promising, with a less than 1 % yield, and unnatural 
hydrogen bonding was seen, the fact that several DNA polymerases used the analogue as a 
substrate made the compound feasible for use in further investigations. DNA pol I (Klenow 
fragment) showed little selectivity in placing 6ed.DTP opposite complimentary bases. 
However, cross-linking occurred only when the analogue was placed opposite the highly 
nucleophilic deoxycytosine or deoxyadenosine. The other important finding was 
polymerization continued beyond the cross-link, indicating that little perturbation had 
occurred within the DNA duplex structure. 
The introduction of cross-linking agents during viral replication (Figure 14) could 
suppress replication by covalently linking genetic material and in__hibiting the digestion of 
viral RNA and transcription of new viral RNA (Figure l ld). In order for this to occur, a 
therapeutic cross-linking agent should possess these four characteristics: (1) it should be a 
nucleoside analogue that is a substrate for DNA polymerases and kinases; (2) the alkylating 
functionality should be small and should not noticeably perturb the DNA duplex, so as to 
avoid repair; (3) the alkylating group should be placed in close proximity to a nucleophile 
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on the complementary strand of DNA; and (4) the analogue should fully retain the Watson-
Crick hydrogen bonding pattern of the parent nucleoside to avoid mismatched-induced 
mutation and ensure its use by DNA polymerases. 
Figure 14. Proposed Insertion of Cross-linking Analogues into Replicating HIV. 
5' 
A 
-
3' 
Viral 
RNA 
5' 3' 
B 
+ 
3' 5' 
Viral Viral 
RNA DNA 
3' 
5' 
Viral 
DNA 
C 
-
3' 5' 
Viral Viral 
ONA ONA 
D 
A= Reverse Transcriptase synthesis of the RNA-DNA hybrid 
B = Ribonuclease H digestion of the viral RNA 
C = DNA Polymerase synthesis of the DNA-DNA duplex 
0 = Integration into the host genome 
E = Transcription into new viral mRNA 
F = Translation and assembly of new virus particles 
Steps B and/or E could be inhibited by cross-linking 
5' 
E F 
-II- -New Virus 
3' 
V,ral 
RNA 
The proposed boron-containing nucleoside analogues could potentially satisfy all 
four of these requirements (Figure 15). It is believed that the triphosphate of 4-
borathymidine could maintain Watson-Crick hydrogen bonding, as previously seen (Figure 
5), when paired with adenosine. With the insertion of the boron-containing nucleoside 
analogue into replicating DNA, the alkylating/cross-linking functionality should be within 
close proximity of the adenosine on the opposite strand. A rotation around the B-0 bond 
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places the alkylating group in a favorable position for nucleophilic attack. If the alkylating 
group is kept small (-OCH2X) there should be little disturbance of the DNA duplex structure. 
Once incorporated into the replicating DNA, the analogues could also be used in another 
fonn of cancer treatment, boron neutron capture therapy. 
Figure 15. Proposed Hydrogen Bonding and Cross-linking of Boron Analogues within 
Replicating DNA 
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Boron Neutron Capture Therapy 
Boron neutron capture therapy (BNCT) has developed as a specified branch of 
radiation therapy in which radiation is generated from the capture reaction of thermal (slow) 
neutrons by nonradioactive 1°B compounds. BNCT has been proposed as part of a binary 
system of cancer treatment in which surgery is the first means of defense and BNCT is used 
to seek out residual cells in the area where a tumor has been removed. Such binary systems 
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currently exist m cancer therapy: chemotherapy. and radiotherapy, surgery and 
chemotherapy, surgery and radiotherapy. Although current methods have proven to be quite 
effective on several types of tumors throughout the body, malignant tumors within the brain 
provide additional challenges. Unlike most malignant tumors, those of the brain possess 
little propensity to metastasize to other organs but are highly infiltrative of the brain itself 61 
Surgery alone cannot meet the therapeutic objective requiring a combination of surgery with 
conventional radiotherapy or chemotherapy. These types of therapy have major limitations 
where the brain tissue is concerned. Conventional radiotherapy must be administered at a 
dose high enough to destroy cancer cells, the magnitude of which is enough to seriously 
compromise normal brain cells. 62 In addition, the radiation is unable to locate and destroy 
tumor cells whose precise location is not known. The most obvious limitation of 
chemotherapy is that drugs administered to destroy tumor cells are not normally confined 
to the target cells but can also adversely affect normal brain cells. Additionally, reversing 
the toxic effects of administered radiation and/or chemotherapy is not possible. Researchers 
interested in BNCT have had these limitations in mind while working to develop a better 
form of therapy. 
During the development of neutron capture therapy over the past 60 years, several 
radioactive and nonradioactive nuclides were targeted for investigation as a result of their 
ability to absorb thermal or slow neutrons. 63 In the long-term investigation of these nuclides, 
three attributes were established as guidelines for considering new nuclides. The first of 
these was a search for high capture cross sections for thermal neutrons. The values shown 
in Table 164 are large by nuclear standards, many are more than 2 orders of magnitude 
greater than observed for normal tissue composition (Table 2).64 
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Table 1. Capture Cross Section Values of Various Nuclides for Thermal Neutrons 
cross section cross section 
nuclide capture valuea nuclide capture valuea 
6Li 942 151Eu 5800 
10B 3838 155Gd 61000 
22Na6 32000 157Gd 255000 
58Cob 1900 164Dy 1800 
113Co 19800 · 1840s 3000 
1261b 6000 199Hg 2000 
135Xeb 2600000 23°Fab 1500 
l48mpmb 10600 235Ub 580 
149Sm 42000 241Pub 1010 
______ ,,. .. _ - .. - - -· - - =-·-----""-ll#- - - - ,, 
a Cross section capture values in barns { 1 barn = 10·24 cm2) 
6 Radioactive 
Table 2. Thermal Neutron Capture Cross Section Values of Tissue Elements and Their 
Percentages 
weight(% cross section weight(% cross section 
nuclide in tissue) _ Ca£ture valuea nuclide in tissue2 _ capture valuea 
H 10.00 0.332 p 1.16 0.18 
C 18.0 0.0034 s 0.20 0.53 
N 3.0 1.82 Cl 0.16 32.68 
0 65.0 1.8 X 10-4 K 0.20 2.1 
Na 0.11 0.43 Ca 2.01 0.4 
Mg 0.04 0.053 Fe 0.01 2.57 
a Cross section capture values in barns (1 barn= 10·24 cm2) 
Second, the nature of the fission products needed to be considered. Identity of the fission 
products helped determine whether these components could be confined to the cell of origin 
or whether they produce radiation which might leave the cell and cause damage to the 
surrounding tissue. Third, radioactive nuclides were quickly removed from the studies due 
to an inability to confine these nuclides to malignant cells, causing exposure of normal 
structures to undesired radiation. 
From the nuclides that have been studied, a brief history of neutron capture therapy 
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can be constructed to show how the three attributes mentioned were established. Early in 
the development of NCT, 235U was investigated as a potential nuclide.65•66 The fission 
particles from the capture of thermal neutrons by radioactive 235U are very large and of 
relatively low energy. Because of these two properties the destructive radiation would be 
confined to the cell in which capture takes place. Unfortunately, most uranium compounds 
are toxic, and though biologically stable ligands of uranium have been synthesized, they are 
of no use when toxicity is considered. Nonradioactive 6Li was considered at the same time 
as 235U.67•68 Due to the size and energy of the particles released during fission (Figure 16), 
6Li appeared to be a promising nuclide. The large, high linear energy transfer· (LET) 
particles could be confined to a radius of9-10 µm, approximately the dimensions of a single 
Figure 16. Neutron Capture by 6Li 
cell. The only limitation is that 6Li is an alkali metal and under biological conditions 6Li 
compounds are broken down to lithium cations. Nonradioactive boron-IO soon came into 
the picture as a potential nuclide for several reasons. Among the top reasons were natural 
abundance (20% of natural boron), fission particles (Figure 17) similar to 6Li,69"72 and small 
atomic size that would permit its replacement of carbon in many organic structures. 
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Figure 17. Neutron Capture by 10B. 
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The 10B nuclide was eventually chosen as the focus of synthetic studies due to the stability 
of boron-containing compounds with structures and chemical and physical properties 
analogous to their carbon counterparts. Hydrolytically and metabolically stable compounds 
containing covalent bonds with various heteroatoms and boron clusters (polyhedral borane 
anions and carboranes) have already been synthesized and studied. However, the search for 
possible nuclides continued with more recent investigation of 157Gd.13-75 Though 157Gd 
possesses a capture cross section 66 times greater than boron-10, the radiation emitted 
counteracts this benefit. The fission products from this nuclide are gamma-rays and Auger 
and Coster-Kronig electrons. 76 Gamma-rays are not confined to the cell where capture 
occurs. Auger and Coster-Kronig electrons have such a low energy that the nuclide must be 
closely associated with the tumor cell DNA to have any effect. 
The objective of BNCT . is to destroy tumor cells and processes without 
compromising nearby or contiguous normal tissue. Unlike conventional radiation, neutron 
capture therapy promises to be able to eradicate tumor cells whose precise location may not 
be fully known so residual cancer cells do notbecome foci for recurrences. However, the 
current limitations of the therapy include a lack of information regarding the permeability 
differences between tumor and contiguous normal tissues depending on the biochemical 
differences between the cell types. The assumption has been made that malignant cells 
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would have a greater uptake rate and radiation sensitivity than normal tissues. 
The question remains, in the minds of researchers, as to whether or not compounds 
containing thermal neutron absorbing nuclides can be designed and synthesized that are 
capable of selectively targeting malignant cells and at a concentration level sufficient to 
deliver an effective radiation dosage. As a means of focusing on this question, research has 
been divided into three areas: design, synthesis, and evaluation of more selective tumor 
targeting agents; optimizing delivery; and improving neutron beam characteristics from 
reactors and accelerators. 
Design and synthesis of selective tumor targeting agents is aimed at realizing four 
important parameters: (1) achieving tumor concentrations in the range of20-35 µg 1°B/g; (2) 
a tumor:normal tissue differential greater than l; (3) sufficiently low toxicity so that the dose 
administered would be well tolerated; and (4) a concentration differential would.persist 
throughout the neutron irradiation period.77 A concentration of 20-35 µg 1°B/g or 109 1°B 
atoms/cell must be achieved to minimize the contribution of radiation from hydrogen and 
nitrogen in the tissue exposed to the neutron beam (Figure 18). At this concentration, 85% 
of the radiation dose comes from the 1°B capture reaction. The nonradioactive nuclide exists 
as 20% of natural boron which can be activated by 0'.025 e V neutrons to produce high LET 
particles capable of eradicating boron-containing tumor cells without causing damage to 
surrounding tissues by being confined to a radius of 9-10 µm. In addition, neutrons at an 
energy of 0.025 eV are below the threshold energy required to ionize tissue components. 
The use of such a low-energy source would allow irradiation of boron-containing cells 
without disturbing other tissue components. 
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Figure 18. Neutron Capture by 1H and 14N in Normal Tissue. 
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Compound design continues to focus on analogs of cellular building blocks in which 
carbon has been replaced by boro~ generating isosteres that offer the potential for 
biologically simulating the parent compounds. The knowledge that tumor cells are in· 
various stages of rapid cell division and may be in search of the constituents needed for 
replication provides the basis for this particular focus. These boron-containing isosteres 
could have the capacity to compete with the natural substrates. Such competition would 
allow for incorporation of the fraudulent building blocks and preparation of the tumor cell 
for BNCT. As is always the case, toxicity of such compounds is of great importance. Since 
the synthetic analogues are meant to very closely mimic the natural components, there is 
potential for the molecules to trigger or suppress biochemical systems in a toxic manner. 
Of all the possible cellular building block analogues, potential precursors of nucleic 
acids continue to be the main thrust of chemical efforts. With the main target for the high 
LET radiation generated by the boron neutron capture reaction being the nucleus (genetic 
material) of the tumor cell, it is only rational to search for analogues of the purines and 
pyrimidines which comprise DNA and RNA. 
There are many approaches to obtaining structural analogues of purines and 
pyrimidines. Boron may be inserted into the ring structure in place of carbon. 78-85 When 
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boron is flanked by two nitrogen atoms, the heterocycle may be easily formed but this 
linkage is very hydrolytically unstable. Such molecules have been synthesized with the 
addition of bulky or aromatic groups for stability but were found to no longer biochemically 
emulate the normal substrates. The boron moiety may also be attached to a pyrimidine 
nucleus. 
The optimization of delivery.of neutron absorbers is most pertinent with the potential 
treatment of brain tumors. The search for molecules that can cross the blood- brain barrier 
continues, as other methods of introduction are considered highly invasive. Among the 
current methods being used are intratumoral injection, implantation of sustained release 
polymers,86 convection-enhanced delivery, blood-brain barrier disruption, and transport 
through cationization. 77 
Current neutron beams contain a broad spectrum of energy: thermal, epithermal, and 
fast neutron, in addition to gamma rays. Thermal neutrons have an energy below the 
threshold value for scattering interaction between neutrons and hydrogen. Energies of 
greater than 10 keV cause scattering that produces protons capable of ionizing tissue 
components. Epithermal neutron beams consisting of0.5 to 10keV87 are being developed, 
for the treatment of more deep-seated tumors of the brain, to counteract the dissipation of 
thermal neutrons. As the epithermal beams traverse the tissue, they become "thermalized" 
by losing energy to the surrounding tissue. The last two types of radiation in current neutron 
beams contribute radiation in a nonselective manner. The presence of these intense types 
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of radiation gives rise to the need for narrowed neutron sources from reactors and 
accelerators. 
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CHAPTER TWO 
STUDIES TOW ARD THE SYNTHESIS OF 4-BORATHYMIDINE 
Oklahoma State University 
The boron-containing thymidine analogue 4-borathymidine (4BT, Figure 19) has 
been designed for investigation of DNA replication, alkylation, and repair by introducing a 
functionality that allows for attachment of a potential reporter group or reactive moiety to 
the exocyclic oxygen at the 4-position. The key design feature of 4BT is the replacement 
of the thymidine C4 carbonyl group ( C=O) by an alkyl borinate (B-0-R). The borinate may 
allow traditional Watson-Crick hydrogen bonding interactions in duplex DNA to be 
maintained, whereas attachment of a reporter group or reactive center to 04 of thymidine 
disrupts normal Watson-Crick hydrogen bonding due to loss of the donor hydrogen atN3 
(Figure 19). 
Figure 19. Comparison of Watson-Crick Hydrogen Bonding Patterns. 
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Synthesis of an analogue possessing an electrophilic alkyl borinate (B-0-RX, X = 
Cl, Br, I) fonctionality introduces the possibility of alkylation of the complementary amino 
group, thereby forming a covalent interstrand cross-link between two nucleic acid strands. 
For this to be accomplished, 4BT must be incorporated into DNA as an analogue of 
thymidine without disrupting the inherent helical structure. Therefore, planarity of the 
boron-containing base is essential. A crude examination of the structural similarities, 
specifically molecular shape and planarity, to thymidine (Figure 20) make 4BT attractive as 
a potential antiviral/anticancer therapeutic. 
Figure 20. Three-dimensional Study Comparison of Thymidine to 4-Borathymidine ( 4BT) 
Structural Similarity Planarity 
I 
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It has been established that at least for some anticancer therapeutics, alkylation and 
cross-linking are the mechanisms by which DNA replication and transcription is inhibited. 1-5 
The main drawback of the commonly used alkylating drugs is their inability to selectively 
target DNA in diseased cells (therapeutic cytotoxicity) as opposed to DNA in normal healthy 
cells.4'6-,8 Since DNA alkylation has also been implicated in mutagenesis, it is clear that any 
clinically useful alkylating/cross-linking agent must strike a delicate balance between 
toxicity and mutagenicity. 
Another promising anticancer strategy besides DNA alkylation is boron neutron 
capture therapy,9•10 currently in clinical ·trials. In this therapy, boron-rich tumor cells are 
selectively destroyed by the high-energy decay products 4He2+ and 7Li+ emitted when 1°13 
captures a thermal (slow) neutron. A nucleoside analogue containing boron that can act as 
a substrate for DNA polymerases may allow tumor cells to accumulate boron in sufficiently 
high quantities as to make this a potentially useful alternative to the current boron-based 
drugs.9-13 
Results and Discussion 
The three major issues considered in the synthesis of 4BT were (1) how to prepare 
the required boron intermediate(s), (2) how to prepare the boron-containing heterocyclic 
base, and (3) how to install the ribose moiety. 
The synthesis of the key boron reactant 5 is shown in Scheme 1. Reaction of l-
ethoxy-1-propyne (3)14' 15 ( derived from chloroacetaldehyde diethyl acetal, 1) with catechol 
borane (4), gave Z-(l-ethoxy-l-propen-2-yl)-1,3,2-benzodioxaborole (5). 16 The 
hydroboration reagent added across the triple bond in a syn orientation17'18 with the boron 
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attached exclusively to C2 of the propene. · 
Scheme 1. Preparation of Z-(1-Ethoxy-1-propen-2-yl)-1,3,2-benzodioxaborole 
1 
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To test the feasibility of preparing the desired boron heterocycle, compound 5 was 
reacted with N-benzylurea (6) as depicted in Scheme 2. Trials using various solvents 
( ethanol, methanol, acetonitrile, ethyl acetate, N ,N-dimethylfonnamide, acetone, ether, 
tetrahydrofuran, and dimethyl sulfoxide) with an acid catalyst (sulfuric, acetic, phosphoric 
acids), a base catalyst ( anhydrous ammonia, ammonium hydroxide, sodium ethoxide ), or no 
catalyst were performed. Of all the combinations, the reaction carried out in DMSO, upon 
being chromatographed on silica gel, gave a product whose 1H NMR, 13C NMR, and F AB 
MS data were consistent with that expected for N3-benzyl-a4-ethyl-5-methyl-4-
borapyrimidin-2-one (7) or the corresponding Nl-benzyl compound 8. After demonstrating 
the validity of the method, 7 ( and 8, after removal of the benzyl group) can potentially be 
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glycosylated, 19•24 2'-deoxygenated, 19,2s and deprotected26 according to literature procedures 
to provide 4BT. 
Scheme 2. Attempted Synthesis of N3-Benzyl-a4-ethyl-5-methyl-4-borapyrimidin-2-one 
(N3-Benzyl-a4-ethyl-4-borathymine) 
5 6 
7 8 
DMSO 
OR1 I 
H,Cl('NH 
HO~_,lO 
OH 
4BT 
During further characterization of 7 and 8, an alternative route to 4BT was pursued; 
This alternative route (Scheme 3) required the synthesis of a fully protected ribofuranosyl 
urea 14 for cyclization with 5. D~Ribose (9) was protected as its 2,3-0-isopropylidene acetal 
10 using acid catalysis. 27'28 Subsequent protection of the 5-hydroxyl as its tert-
butyldiphenylsilyl (TBDPS) ether9 gave the protected ribofuranose 11, which was treated 
with triphenylphosphine and carbon tetrachloride to form a ribosyl chloride30 that was 
immediately reacted with sodium azide to provide 5-0-tert-butyldiphenylsilyl-2,3-0-
isopropylidene ribofuranosyl azide (12).31•33 The azide 12 was then reduced under standard 
conditions31 ,34 and reacted with benzyl isocyanate to provide the fully protected ribofuranosyl 
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urea 1431•35 in 19% yield for five steps. 
Scheme 3. Synthesis of .N3-Benzyl-5-0-tert-butyldiphenylsilyl-2,3-0-isopropylidene 
Ribofuranosyl Urea 
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At this point, based on the reaction of 5 with 6, the reaction of 5 with 14 in the presence of 
DMSO (Scheme 4) should have given the fully protected ribofuranose form of analogue 15; 
this was not observed. 
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Scheme 4. Proposed Synthesis of 4-Borathymidine 
5 + 14-
R = alkyl 
15 
R1 = H, alkyl 
48T 
The additional investigation to verify the identity of compound 7 involved elemental 
analysis in which boron was assayed in addition to carbon, nitrogen, and hydrogen. 
Unexpectedly, the elemental analysis that was returned indicated no boron was present in 
the sample. A curious result for what appeared to be a straightforward interpretation of the 
initial data. Initially, LR-FAB MS supported the calculated formula mass of 244, seen as 
MH+ equal to 245, 1H NMR splitting patterns and integration were consistent with the 
proposed structure, and 13C NMR showed 11 signals with the carbon next to the boron not 
being observed {Figure 21 ). This is a common phenomenon caused by the quadrupolar 
moment of boron broadening the signal of the neighboring carbon. 
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Figure 21. Initial 13C NMR of Compound 7 
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Repeated investigation of 7 led to data that was intriguing. LR-FAB MS now 
indicated a fonnula mass of 228 and 13C NMR showed 12 signals (Figure 22). This new data 
paved the way for further investigation into what was actually occurring. First, a structure 
needed to be proposed from the new data. Compound 16 matched the data provided by 
elemental analysis, LR-F AB MS, 1H NMR and 13C J\i1MR so an investigation into the origin 
of this product began. 
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Figure 22. Spectra Obtained During Further Investigation of Compound 7 
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Retrosynthetically, the possible involvement of propionaldehyde in the reaction was 
suggested (Figure 23). In order to examine this possibility, the reaction of 5 with 6 in the 
presence of DMSO was repeated with the addition of propionaldehyde and with the addition 
ofbutyraldehyde to observe any changes that may occur in the outcome of the reaction. In 
the propionaldehyde case only 6% of the desired product was observed, and with 
butyraldehyde, the product of interest was not observed indicating that the reaction did not 
proceed as proposed. 
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Figure 23. Retrosynthetic Analysis for Compound 16 
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The work presented in the preceding pages shows the complexity of building an 
acyclic precursor for the purpose of incorporating boron into a heterocyclic compound. The 
method of introducing boron must be carefully chosen so as not to destroy the acyclic 
precursor before the boron is securely in place. Among the many considerations to be taken 
into account is the bond strength between boron and other atoms, such as carbon, nitrogen, 
oxygen, and the halogens. The boron-nitrogen bond is rather labile compared to bondswith 
carbon and oxygen and, therefore, posed a problem in the desired synthesis. 
The observation to be made from this work is that, when attempting to form a boron-
nitrogen bond, abundant spectral data must be taken to ensure that the desired product has 
indeed been achieved. As a result of this observation, future work includes 11B NMR data 
to support the assumption that boron is present in the molecule. 
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Experimental 
General Synthetic Procedures. NMR spectra were obtained on Gemini 300 or 
Unity Inova 400 or 600 MHz spectrometers from Varian. Unless otherwise stated, the 1H 
and 13C NMR spectra were recorded in CDC13 and referenced to either internal TMS or to 
the central line of the residual solvent multiplet. Infrared spectra were obtained using KBr 
on a System 2000 FT-IR instrument from Perkin-Elmer. Gas chromatography-mass 
spectrometry (electron ionization) was performed on a Hewlett-Packard Gl800A GCD 
system. Low resolution fast atom bombardment (LR-F AB) mass spectra were obtained ori 
a model ZAB-2SE VG Analytical Limited spectrometer. The high resolution fast atom 
bombardment (HR-FAB) mass spectra were performed by the Washington University 
Resource for Biomedical and Bio-organic Mass Spectrometry, St.- Louis, MO. Elemental 
analyses were performed by Galbraith Laboratories, Knoxville, TN. Melting points were 
determined on a Thomas Hoover apparatus and are uncorrected. All reactions were run 
under an inert atmosphere of nitrogen using glassware dried at 100 ° C. D-Ribose was dried 
under vacuum with P20 5• When used as a reaction solvent, chlorofonn was ethanol-free. 
Other solvents were dried using established procedures and appropriate drying agents: 
dimethylsulfoxide (DMSO) and dimethylforamide (DMF) over 3'A sieves; ethanol, ethyl 
acetate, and methanol over4'A sieves; acetone distilled from CaS04; triethylamine (Et~) 
distilled from KOH; acetonitrile distilled from CaH2; carbon tetrachloride distilled from 
P20 5• Unless otherwise noted, reactions were dried over Na2804 followed by filtration 
through glass wool. Solutions were evaporated in vacuo using a rotary evaporator at 30°C 
and 20 mm Hg (water aspirator). A cylinder ofDrierite ™ (W.A. Hammond) was placed in 
the vacuum line between the aspirator and rotary evaporator to protect the contents from 
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moisture. Drying in vacuo refers to removal of residual solvent using an oil pump ( <0.1 mm 
Hg) at room temperature. Thin-layer chromatography was accomplished using Machery-
Nagel Polygram Sil G/UV™ plates with detection using either ultraviolet light(254 nm) or 
p-dimethylaminobenzaldehyde stain36• Purification was accomplished by column 
chromatography37 on silica using combinations of chlorofonn (C), ethanol (E), and hexanes 
(H) as the main solvents. Chemicals were purchased from Aldrich and solvents from Fisher 
Scientific unless otherwise stated. 
1-Ethoxy-1-propyne (3). A 1-L, 3-neckedround-bottomed flask equipped with a 
dry ice condenser, a mechanical stirrer, and a gas inlet tube was placed in a dry ice-acetone 
bath. After flushing with nitrogen, anhydrous ammonia was introduced until 600 mL of 
liquid ammonia had collected. The gas inlet was replaced by a septum and the cooling bath 
was lowered. To the ammonia was added iron(III) nitrate nonahydrate (0.59 g, 1.5 mmol) 
followed by a small piece of freshly cut sodium. Once hydrogen evolution ceased, small 
pieces of sodium were added over a 20 min period until 35.8 g (1.56 mol) had been 
introduced. The reaction was allowed to stir until the dark blue color dissapeared to give 
a dark gray suspension. To the reaction was added chloroacetaldehyde diethyI·acetal (76.0 
mL, 77.4 g, 0.51 mol) at a rate of I mUmin by syringe pump. [Note: Excessive foaming ,vas · 
controlled by stopping the addition or immersing the flask in the cooling bath.] . After 30-60 
min, the mixture became light gray and methyl iodide (69.0 mL, 157 g, 1.1 mol) was added 
slowly (0.3-1.6 mL/min) by syringe pump. The mixture was stirred vigorously for 2.5 h, 
after which the septum was replaced by a pressure-equalizing addition funnel. Cooled, 
saturatedammoniumchloride(30mL)wascautiouslyadded,followedbypentane(120mL) 
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and additional cooled ammonium chloride (370 mL). The contents of the flask were 
transferred to a 2-L separatory funnel, the layers separated, and the aqueous layer extracted 
with pentane (2 x 75 mL). The combined organic layers were filtered through glass wool 
to remove emulsions, dried with MgS04, and filtered. Distillation of the pentane solution 
gave 26.3 mL (22.0 g, 261 mmol, 50%) of l-ethoxy-1-propyne as a colorless liquid: bp 88-
90 °C. 1H NMR o 4.01 (q, 2 H, J = 7.1 Hz, CH2), 1. 75 (s, 3 H, =CCH3), 1.35 (t, 3 H, J = 7.1 
. 13 ~ Hz, -CH2CH3). C NMR u 88.03, 73.62, 32.43, 14.25, 1.47. 
Z-(1-Etboxy-1-propen-2-yl)-1,3,2-benzodioxaborole (5). Catecholborane (1,3,2- · 
benzodioxaborole, 1.09 g, 9.1 mmol)wasaddedto 1-ethoxy:.l-propyne(J, 0.82 g, 9.7nimol) 
under nitrogen at O ° C. The reaction mixture was stirred at 70 ° C for 5.5 h. Distillation ( 0. 4 
mm Hg) of the reaction mixture gave 1. 09 g (5 .3 mmol, 58%) of Z-(1-ethoxy-1-propen-2-yl)-
1,3,2-benzodioxaborole as a colorless liquid, bp 74-77 °C. [Note: Z-(l-ethoxy-l-propen-2;.. 
yl)-1,3,2-benzodioxaborole is air and moisture sensitive. A deep red color appears upon 
contact with air but the compound is stable when stored under N2 at 5 °C.] 1H NMR o 7.08 
(q, 1 H,J= 1.5 Hz, Hl), 7.19-7.00 (m, 4 H,J= 7.1 Hz, ArH), 4.05 (q, 2 H,J= 7.1 Hz, CH2), 
1.80 (d, 3 H, J= 1.5 Hz, =CCH3), 1.35 (t, 3 H, -CH2CH3). 13C NMR o 159.85, 149.05, 
122.75, 112.49, 69.50, 15.97, 10.06. The alkene carbon (C2) attached to boron was not 
observed due to strong quadrupolar line-broadening. 38 
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NJ-Benzyl-O"-ethyl-5-methyl-4-borapyrimidin-2-one (NJ-Benzyl-O"-ethyl-4- . 
borathymine, 7) or Nl-Benzyl-O'-ethyl-5-methyl-4-borapyrimidin-2-one (Nl-Benzyl-
O'-ethyl-4-borathymine, 8). A solution ofbenzylurea (81 mg, 0. 59 mmol) and Z-( 1-ethoxy-
1-propen-2-yl)-1,3,2-benzodioxaborole (5, 100 µL, 104 mg, 0.51 mmol) in DMSO (1 mL) 
was stirred at room temperature for 25 h then heated to 65 °C for an additional 28 h. The 
solvent was evaporated under vacuum on a rotary evaporator and the resulting syrup 
chromatographed (100% C--+ 100% E) to yield 42.0 mg (172 mmol, 30%) of7 or 8, Rc0.55 
(90:10 C:E). Initial Data: MS (LR-FAB) mlz 245 (Mlr+). 1HNMR <> 7.36-7.28 (m, 6 H, Ar 
and NH), 6.93 (q, 1 H, J = 3.7 Hz, H6), 5.05 {s, 2 H, -CH2-), 2.61 {q, 2 H, J = 7.3 Hz, 
-CH2CH3), 1.97 (d, 3 H,J= 3.3 Hz, =G-CH3), 1.24 (t, 3 H,J= 7.3 Hz, -CH3). 13C NMR <> 
180.03, 143.82, 135.61, 129.10, 128.57, 128.46, 127.90, 112.39, 52.89, 29.18, 14.31, 10.65. 
Compound 16 based on revised data from 7: MS (LR-FAB) mlz 228 (Mli+). 1H NMR o 
7.36-7.28 (m, 6 H, Ar and NH), 6.93 (q, l H, J= 3.7 Hz, H6), 5.05 (s, 2 H, -CH2-), 2.61 (q, 
2 H, J = 7.3 Hz, -CH2CH3), 1.97 (d, 3 H, J= 3.3 Hz, =C-CH3), 1.24 (t, 3 H, J= 7.3 Hz, 
-CH3). 13C NMR o 179.92, 156.67, 143.74, 135.64, 128.99, 128.48, 128.34, 112.24, 52.75, 
29.12, 14.23, 10.56. 
2,3-0-lsopropylidene Ribofuranose (10). Acetone (50.0 mL, 681 mmol), 3 A 
sieves (1.86 g), and Dowex 50W-X8[H+] ion exchange resin (1.77 g) were combined. D-
Ribose (3.07 g, 20.0 mmol) was added and the mixture was stirred at room temperature for 
10.5 h. The mixture was filtered, solvent evaporated, and the resultant thick syrup was 
chromatographed (80:20 .... 90:10 EtOAc:petroleum ether) to yield 2.57 g (13.5 mmol, 68%) 
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of2,3-0-isopropylideneribofuranose,~0.61 (EtOAc). MS (LR-FAB)m/z 173(Mfi+-H20). 
1H NMR o ((} anomer) 5.42 ( d, 1 H, J = 6.0 Hz, Hl ), 4.85 ( d, 1 H, J = 6.0 Hz, H2), 4.59 ( d, 
1 H, J = 12.0 Hz, H3), 4.42 (t, 1 H, J = 2.4 Hz, H4), 3.80-3.40 (m, 4 H, H5',5", CH20H, OH), 
1.49 (s, 3 H, CH3), 1.33 (s, 3 H, CH3). 13CNMR o 112.34, 103.24, 87.09, 87.94, 88.15, 
63.91, 26.71, 24.82. 
5-0-tert-Butyldiphenylsilyl-2,3-0-isopropylidene Ribofuranose (11 ). A solution 
of tert-butyldiphenylsilyl chloride (2.1 mL, 2.2 g, 8.1 mmol) in DMF (12.5 mL) was slowly 
added, via 250 µm capillary over 4 h, to a stirred mixture of 2,3-0-isopropylidene 
ribofuranose (10, 1.07 g, 5.6 mmol) and imidazole (L20 g, 17.7 mmol). After 4.5 h, the 
reaction mixture was diluted with ether (20 mL), washed with H20 (2 x 10 mL), NaCl (10 
mL), dried and evaporated. The crude clear syrup was chromatographed (95:5:0.5 
C:H:Et3N-99: 1 :0.5 C:E:Et3N)to give 2.34 g (5.5 mmol, 97%) of 5-0-tert-butyldiphenylsilyl-
2,3-0-isopropylidene ribofuranose, Rf0.33 (99: 1 C:E). 1HNMRo(majoranomer)7.72-7.37 
(m, 10 H, Ar), 5.35 (d,1 H, J= 10.4 Hz, Hl), 4.72 (d, 1 H, J = 6.0 Hz, H2), 4.61 (d, 1 H, J 
= 6.0 Hz, H3), 4.53 ( d, 1 H, J = 10.4 Hz, H4), 4.28 (s, 1 H, OH), 3.82 ( dd, 1 H, J = 11.3, 2.8 
Hz, H5' or H5"), 3.66 (dd, 2 H, J = 11.3, 2.4 Hz, H5" or H5'), 1.48 (s, 3 H, CH3), 1.32 (s, 3 
H, CH3), 1.06-1.09 (s, 9 H, t-Bu). 13C NMR o 135.94, 135.76, 135.01, 131.81, 131.71, 
130.64, 130.44, 128.32, 128.18, 128.11, 127.92, 112.33, 103.63, 103.60, 87.56, 87.28, 65.70, 
27.10, 27.06, 26.77, 26.68, 25.17, 19.34. 
5-0-tert-Butyldiphenylsilyl-2,3-0-isopropylidene Ribofuranosyl Azide (12). A 
solution of 5-0-tert-butyldiphenylsilyl-2,3-0-isopropylidene ribofuranose (11, 5.19 g, 12.1 
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mmol), carbon tetrachloride (3.4 mL, 5.4 g, 35 mmol), and triphenylphosphine (3.89 g, 14.8 
mmol) in DMF (9.2 mL) was stirred at room temperature for 4.5 h. The reaction mixture 
was poured into a stirred mixture of20 mL of ether, 20 mL of petroleum ether, and 40 rnL 
of ice water. Celite was added and the mixture filtered through a Celite pad. The aqueous 
layer was separated and washed with 1:1 petroleum ether:ether. The combined organic 
layers were dried, evaporated to 1/2 volume, filtered through silica, and evaporated to give 
a crude syrup of 5-0-tert-butyldiphenylsilyl-2,3-0-isopropylidene ribofuranosyl chloride 
which was used directly, Rr0,80 (99:1:0.5 C:E:Et3N). 1HNMR o (major anomer) 7.69-7.36 
(m, 10 H, Ar), 6.09 (s, 1 H,Hl), 4.90 (d, l H,J= 5.9 Hz, H2), 4.83-4.81 (m, 1 H, H3), 4.43-
4.41 (m, l H, H4), 3.87-3.82 (m, 2 H, H5',5"), 1.56 (s, 3 H, CH3), 1.40 (s, 3 H, CH3), 1.05-
1.14 (9 H, t-Bu). 13C NMR o 135.86, 135.81, 135.00, 133.35, 133.20, 130.07, 129.87, 
127.99, 113.43, 98.75, 90.27, 89.67, 81.66, 63.50, 27.07, 27.01, 26.78, 26.71, 25.53, 19.45. 
Acetonitrile (69.0 rnL) and sodium azide (6.59 g, 101 mmol) were added to the crude syrup 
and the resultant suspension was stirred at reflux (80-85 °C) for 7 h, then at room 
temperature for 7 h. After filtration and evaporation, the resulting syrup was 
chromatographed (40:60:0. 5 .... 80:20:0.5 C:H:Et3N) yielding 2.26 g ( 5. 0 mmol, 41 % ) of 5-0-
tert-butyldiphenylsilyl-2,3-0-isopropylidene ribofuranosyl azide, Rf 0.22 (45:55:0.5 
C:H:Et3N). FT-IR (KBr) v 2124 (N3). MS (LR-FAB) mlz 453 (MH+). 1HNMR 6 (major 
anomer) 7.70-7.35 (m, IO H, Ar), 5.18 (d, 1 H, J= 4.0 Hz, HJ), 4.82 (dd, 1 H, J= 6.4, 1.1 
Hz, H3), 4.77 (dd, l H,J= 6.4, 4.0 Hz, H2), 4.27 (broad t, l H, H4), 3.86 (dd, l H,J:= 11.4, 
2.9 Hz, H5' orH5"), 3.69 (dd, l H, J= 11.4, 2.6 Hz, H5" or H5'), 1.59 (s, 3 H, CH3), 1.38 (s, 
3 H, CH3), 1.03-1.10 (9 H, t-Bu). 
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5-0-tert-Butyldiphenylsilyl-2,3-0-isopropylidene Ribofuranosyl Amine (13). The 
reduction of 5-0-tert-butyldiphenylsilyl-2,3-0-isopropylidene ribofuranosyl azide (12) was 
carried out by balloon hydrogenation. A solution of 5-0-tert-butyldiphenylsilyl-2,3-0-
isopropylidene ribofuranosyl azide (12,205 mg, 0.45 mmol) in ethyl acetate (6.0 mL), and 
I 0% Pd/C (25 mg), were stirred under H2 for 2.5 h, filtered through MgS04, and evaporated. 
Drying under vacuum gave 188 mg (0. 44 mmol, 98%) of 5-0-tert-butyldiphenylsilyl-2,3-0-
isopropylidene ribofuranosyl amine as a clear syrup, Rr0.16 (99:1:0.5 C:E:Et3N). MS (LR-
FAB) mlz428 (MH+). 1HNMRo 7.70-7.30(rn, lOH,Ar), 5.14 (d, l H,J=4.0Hz,Hl),4.75 
(dd, 1 H,J= 6.0 Hz, H2), 4.62 (dd, 1 H,J= 6.0, 3.7 Hz, H3), 4.04 (broad t, 1 H,J= 3.1 Hz, 
H4), 3.78 (dd, 1 H,J= 11.0, 3.7 Hz,H5' or H5"), 3.66 (dd, I H,J= 11.0, 3.1 Hz, H5" or H5'), 
2.14 (broads, 2 H, NH2), 1.53 (s, 3 H, CH3), 1.37 (s, 3 H, CH3), 1.08-1.02 (9 H, t-Bu). 
N3-Benzyl-5-0-tert-butyldiphenylsilyl-2,3-0-isopropylidene Ribofuranosyl Urea 
(14). To a stirred solution of 5-0-tert-butyldiphenylsilyl-2,3-0-isopropylidene ribofuranosyl 
amine (13, 42 mg, 0.10 mmol), benzyl isocyanate (40 µL, 43 mg, 0.32 mmol), and CHC13 
(0.75 mL) was added a solution oftriethylamine (20 µL, 15 mg, 0.15 mmol) in CHC13 (0.25 
mL) via a 250 µm capillary fiber. The reaction was stirred at room temperature for 5 h then 
washed with 2 MHCI (1 mL), H20 (1 mL), NaHC03 (1 mL), and H20 (3 x 1 mL). The 
organic layer was dried and evaporated. The crude product was chromatographed (7 5 :25 :0. 5 
C:H:Et3N .... 100 C) to yield 41 mg (7.3 µmol, 73%) of N3-benzyl-5-0-tert-butyldiphenylsilyl-
2,3-0-isopropylidene ribofuranosyl urea as a dark orange solid, Rr0.14 (99: 1 :0.5 C:E:Et3N). 
MS (LR-FAB) mlz 561 (MH+). 1H NMR o 7.66-7.27 (m, 15 H, Ar), 5.85 (dd, 1 H, J = 8.8, 
4.4 Hz,Hl), 5.51 (d, 1 H,J=9.2 Hz, NH), 4.91 (broad t, 1 H,NH-CH2), 4.80 (d, 1 H,J= 
53 
6.2 Hz, H3), 4.60 (dd, 1 H,J= 6.2, 4.4 Hz, H2), 4.47 (dd, 1 H,J= 14.7, 5.5 Hz, PhCH2), 4.41 
(dd, 1 H,J= 14.7, 5.9 Hz, PhCH2), 4.10 (t, 1 H, H4), 3.79 (dd, 1 H,J= 11.0, 3.7 Hz, H5' or 
H5"), 3.67 (dd, 1 H, J = 11.0, 2.7 Hz, H5" or H5'), 1.50 (s, 3 H, CH3), 1.36 (s, 3 H, CH3), 
1.26-1.06 (9 H, t-Bu). 
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CHAPTER THREE 
2-BENZYL-l,4-DJHYDRO-l-HYDROXYTIIlEN0[3,2-c][l,5,2]DIAZABORIN-3(2H)-
ONE 
Synthesis of a Novel Heterocycle 
For quite some time, boron has been recognized as a valuable component of synthetic 
reagents. Only recently has boron emerged on the biological scene with great potential for 
biologically active compounds containing boron. 1 As the scientific community continues 
to search for innovative and effective therapeutic agents, we were motivated to design and 
synthesize nucleoside analogues in which the carbon atom of a pyrimidine or purine is 
replaced by boron. The ability of boron to maintain a trigonal planar conformation similar 
to that of a carbonyl, brought about a curiosity focused on the preservation of the Watson-
Crick hydrogen bonding patterns. Preserving the bond donor and acceptor patterns found 
in parent nucleosides lends to a greater possibility for the designed endocyclic boron-
containing nucleosides (BCNs) to serve as DNA structural probes and as potential inhibitors 
of DNA replication. 
The boron-for-carbon replacement has been successfully used to prepare analogues 
of amino acids2 and peptides/ boron-containing amino acids with pendant boron groups; Ih,4 
as well as exocyclic boron-containing nucleosides with the boron found as a nucleobase,5'6 
sugar, lb or phosphate7 substituent are also known. Known nucleobase analogues with 
endocyclic boron1e,s.-2o provide the most relevant structural information for the work 
described herein. To our knowledge, the task of incorporating such endocyclic boron 
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nucleobases into a nucleoside has not yet been accomplished.21 
Our first attempt at synthesizing a borauracil analogue has previously been described 
and is shown here in Scheme 5. After being unsuccessful at preparing the desired analogue 
by methods adapted from work by Shaw22 and others,23 another approach was investigated. 
Gronowitz has prepared 1,2,3-diazaborine and 1,2-azaborine heterocycles via nickel 
desulfurization of the corresponding tbieno-fused diaza- and azaborines. 
Scheme 5. Attempted Synthesis of a Borathymidine Analogue 
+ 
a, R1 = H 
b, R1 = Bn 
c, R1 = Bn 
The advantage of the Gronowitz thieno-fused pathway is that the boron heterocycle 
can be constructed using a stable starting template, like the aromatic thiophene ring, instead 
of vinyl ureas or alkenyl boronates. Though Gronowitz has reported the synthesis of thieno-
fused diaza- and azaborines, there are no reports describing the preparation of tbieno-fused 
1,5,2-diazaborin-3(2.H}-ones (thieno-fused borauracils)usingthis, or any other, method prior 
to 1998. The few cases in which the l,5,2-diazaborin-3(2H)-one ring system has been 
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reported depict this system stabilized as the benzo-fused 4-borauracil derivative. In the 
reported cases, the 1,5,2-diaz.aborin-3(2H)-one ring system was prepared by reaction of (2-
aminophenyl)boronic acids with isocyanates. Unfortunately, direct extension of this 
approach in an attempt to obtain thieno-fused 4-borauracils would require the synthesis of 
(2-amino-3-thienyl)boronic acid. This route would be likely to suffer from the instability 
of 2-aminothiophenes lacking strong electron withdrawing groups. 
An alternative route to the boron heterocycle was investigated to avoid encountering 
the unstable 2 .. aminothiophene considered in the previous route. The alternative, a less 
common procedure involves synthesis of an acyclic precursor of the desired boron 
heterocycle followed by treatment with an appropriate boron reagent which introduces the 
boron atom and allows cyclization; Upon analysis of the desired thieno-fused 4-borauracil 
structure, 2-thienylurea was chosen as the target acyclic precursor for our synthetic route. 
Preparation of the urea can be considered from two obvious directions, via 2-
aminothiophene or 2-thienylisocyanate. Approach via 2-aminothiophene still posed 
complications so 2-thienylisocyanate became the target intermediate for the preparation of 
2-thienylurea. 
Results and Discussion 
Initially, attempts were made to convert 2-thienylnitrate to (2-thienylnitro )boronic 
acid by methods described by McMurry24 and Gronowitz25 · (Scheme 6a ). After several 
attempts at introducing the boron to the system in this manner, the synthesis of2-thienylurea 
was approached. First, by the possibility of converting 2-thienophenecarbonyl chloride to 
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2-thienylisocyanate by the method of Toselli and Zanirato26 (Scheme 6b ). As this method 
proved unsuccessful, further investigation led to the formation of 2-thienophenecarbonyl 
Scheme 6. Synthetic Studies Toward a Stable Template for Preparation of2-Benzyl-l,4-
dihydro-l-hydroxythieno[3,2-c ][ 1,5 ,2]diazoborin-3(2H)-one 
a 
b 
n-Buli 
TM EDA 
Et20 
<\,Cl TMSA, CCl4 
0 
((Li B(OBuh 
S N02 H+ workup 
azide by conversion of 2-thienophenecarbonyl chloride using sodium azide in aqueous 
acetone (Scheme 7). Azide 18 was then converted to 2-thienylisocyanate (19}in 37% yield 
via Curtius rearrangement which required heating a carbon tetrachloride solution of 18 at 
100 °C for 13 h. Examination of the 1H NMR spectrum of the crude 19 after evaporation 
of the carbon tetrachloride showed that the 2-thienylisocyanate produced was sufficiently · 
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Scheme 7. Preparation of N-Benzyl-N'-(2-thienyl)urea 
~ NaN3 r Oy l CCl4 (1. S Cl acetone, H20 S N3 I 100 °C, 13 h S--..__N=C=O 
0 L o J 
17 18 19 
pure to proceed, although purification could be accomplished by vacuum distillation. The 
addition of benzylamine to a solution of isocyanate 19 in carbon tetrachloride precipitated 
N-benzyl-N'-2-thienylurea (20) as a white solid in 94% yield. Finally, 2-benzyl-1,4-dihydro-
l -hydroxythieno[3 ,2-c] [1,5 ,2]diazaborin-3(2H)-one (21) was produced by heating a solution 
of the urea 20 in 1,2-dichloroethane containing 1.3 equivalents of boron trichloride and 
catalytic aluminum chloride. The desired heterocycle 21 was purified by preparative HPLC 
(C11, column, 65:35 water:acetonitrile) and characterized by 1H, 13C, and 11B NMR 
spectroscopy in addition to elemental analysis and high resolution fast atom bombardment 
mass spectrometry. 
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NMR Studies of 
2-Benzyl-1,4-dihydro-1-hydroxythieno[3,2-c] (1,5,2]diazaborin-3(2H)-one 
1H, 13C, and 11B NMR data for compound 21 were recorded in a variety of solvents 
to confirm the proposed structure. 1H NMR data (Table 3) is in agreement with the 
proposed structure, as indicated by the observance of a single broad, exchangeable signal 
(the proton on N4), a single sharper, exchangeable signal (the proton on 01), two doublets 
(J = 5.4 Hz) for the thiophene protons (H6 and H7), and a singlet for the benzyl methylene 
group. The 13C Nivm.. data provided additional evidence for the structure of 21. Compound 
21 gave only nine observed carbon signals while urea 20 clearly showed ten carbon signals. 
This piece of data was expected due to the strong quadrupolar line broadening of boron8•9•15 
which generally precludes observation of the carbon signal for the carbon directly attached 
to the boron. Finally, the ability of the boron within compound 21 to remain trigonal planar 
when exposed to various solvents was investigated using 11B NMR. 
Boron-11 NMR spectroscopy has been used as a very sensitive probe of boron 
hybridization26 to study the relative tendency of boron heterocycles to undergo a change 
from trigonal to tetrahedral due to solvent addition.8-10.2° The chemical shifts (Table 3) of 
approximately 33 ppm using the boron trifluoride·etherate scale are indicative of a trigonal 
boron atom. We see no evidence for tetrahedral boron in the uB NMR spectra (no signal 
approximately 20-30 ppm upfield from the observed signal) in any of the solvents used, 
including methano1-d4. However, previously reported data for the benzo-fused l,5,2-
diazaborin-3(2H)-one ring system indicated partial 10•20 or complete20 conversion to the 
tetrahedral adduct in the presence of methanol-d4. Though less sensitive as indicators of a 
change from trigonal to tetrahedral hybridization, the 1H and 13C NMR spectra also show no 
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evidence for tetrahedral boron. To date, there is no explanation for the apparent resistance 
of 21 versus the benzo-fused ring system towards tetrahedral adduct formation. 
Table 3. 1H and 11B NMR Data for 2-Benzyl-l,4-dihydro-l-hydroxythieno[3,2-
c][l,5,2]diazaborin-3(2H)-one (21) 
NH OH H6 H7 Ph CH2 Bld 
acetone -d6 • 10.31 8.42 7.22 6.85 7.41 (appdm. 7.6 4.87 33.5 
Hz) 
(brs) (s) (d, 5.4 Hz) (d, 5.4 Hz) 7.26(apptm, 7.6Hz) (s) 
7.1.7 (apptm, 7.5 Hz) 
deuteriochloroform b 8.79 4.79 6.99 6.77 7.44 (app d, 6.9 Hz) 4.91 
(brs) <s) (d, 5.4 Hz) (d, 5.4 Hz) 7.34-7.22 (m) (s) 
acetonitrile-d3 b 9.46 7.01 7.15 6.81 7.32-7.19 4.80 33.7 
(brs) (s) (d. 5.4 Hz) (d, 5.4 Hz) (m) (s) 
methanol-d4 • ex.ch. ex.ch. 7.36 6.92 7.35-7.14 4.81 32.3 
(d, 5.5 Hz) (d, 5.4 Hz) (m) (s) 
a At600MHz 
b At300MHz 
• At400MHz 
d AJl 11B NMR. spectra were recorded at 128 MHz 
Conclusions 
The successful synthesis of 2-benzyl-1,4-dihydro-1-hydroxythieno[3,2-
c ][ 1,5,2]diazaborin-3(2H)-one (21) has renewed interest in obtaining other boron-containing 
analogues of nucleobases prepared by methods similar to those described above. To date, 
2-benzyl-1, 4-dihydro-1-hydroxythieno[3,2-c] [1,5 ,2]diazaborin-3(2H)-one has not been 
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assayed to determine its susceptibility to glycosylation and phosphorylation or its usefulness 
as a therapeutic agent. However, with the data obtained through 11B NMR, 2-benzyl-1,4-
dihydro-1-hydroxythieno[3 ,2-c ][ 1,5 ,2]diazaborin-3(2H)-one appears to remain unchanged 
in a variety ,of solvents. This stability was observed as the absence of a tetrahedral boron 
signal, indicating a lack of coordination between the solvent and boron atom. The 
maintenance of the trigonal boron suggests that if2-benzyl-1, 4-dihydro-1-hydroxythieno[3,2-
c ][l ,5 ,2 ]diazaborin-3(2H)-one could be glycosylated and phosphorylated, there would be 
great expectations for the heterocyclic base to be able to mimic natural nucleotides during 
DNA and RNA replication. 
Experimental 
General synthetic procedures. NMR spectra were obtained on Gemini 300 or 
Unity lnova 400 or 600 MHz spectrometers from Varian. Unless otherwised stated, the 1H 
and 13C NMR spectra were recorded in CDC13 and referenced to either internal TMS or the 
central line of the residual solvent multiplet. The 11B NMR spectra are reported on the 
boron trifluoride·etherate scale ( 6 = 0 ppm); the spectra were referenced by setting the signal 
of an external trimethyl borate standard to 18.3 ppm. Infrared spectra were obtained in 
carbon tetrachloride solution on a System 2000 FT-IR instrument from Perkin-Elmer; 
ultraviolet spectra were obtained on a Hewlett-Packard 843 Diode Array Spectrophotometer; 
gas chromatography-mass spectrometry {electron ionization) was performed on a Hewlett-
Packard G1800A GCD system; low resolution fast atom bombardment (LR-FAB) mass 
spectra were obtained on a model ZAB-2SE VG Analytical Limited spectrometer; the high 
resolution fast atom bombardment (HR-FAB) mass spectra were performed by the 
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Washington University Resource of Biomedical and Bio-organic Mass Spectrometry, St. 
Louis, Mo. Elemental analyses were performed by Galbraith Laboratories, Knoxville, TN. 
The HPLC system used was a Waters 600E pump/controller outfitted with a 996 photodiode 
array detector. Analytical HPLC runs used a 4.6 x 260 mm (5 micron) MicrosorbMV™ C 18 
reversed-phase column (1 mL/min) from Rainin; preparative runs used a Dynamax™ 21.4 
x 250 mm (8 micron) column (12 mL/min) also from Rainin. Melting points were 
determined on a Thomas Hoover apparatus and are uncorrected. All reactions were run 
under an inert atmosphere of"nitrogen using giassware dried at l00°C. The carbon 
tetrachloride was dried by distillation from P 20 5; all other chemicals and solvents were used 
as received. Unless otherwise noted, reactions were dried over N~S04 followed by filtration 
through glass wool. Solutions were evaporated in vacuo using a rotary evaporator at 30°C 
and 20 mm Hg (water aspirator). A cylinder ofDrierite™ (W. Hammond) was placed in the 
vacuum line between the aspirator and rotary evaporator to protect the contents from 
moisture. Drying in vacuo refers to removal of residual solvent using an oil pump ( <0.1 mm 
Hg) at room temperature. Thin-layer chromatography was accomplished using Machery-
Nagel Polygram Sil G/UVTM plates with detection using either ultraviolet light (254 nm) or 
p-dimethylaminobenzaldehyde stain28• Chemicals were purchased from Aldrich and solvents 
from Fisher Scientific unless otherwise stated. 
2-Thienylisocyanate (19). A solution of2-thiophenecarbonyl chloride ( 4.0 mL, 5.6 
g, 38 mmol) in acetone (20 m.L) was cooled to O °C and treated by dropwise addition of a 
solution of sodium azide (2.87 g, 44.1 mmol) in water (24 mL). The cooled solution was 
stirred for 3.5 h until analysis by GC-MS indicated complete conversion of 17 to 2-
65 
thiophenecarbonyl azide (18). FT-IR v 2154, 2129 (N3), 1687 (C=O). Carbon tetrachloride 
(20 mL) and saturated sodium bicarbonate (10 mL) were added, the layers separated, and the 
organic layer was dried and evaporated. Curtius rearrangement was performed by dissolving 
the above crude azide 18 in carbon tetrachloride (25 mL) and heating in a heavy-walled glass 
pressure vessel sealed with a threaded Teflon plug at l00°C for 13 h. Caution: This step 
should be conducted behind a blast shield. After cooling to room temperature, the solvent 
was removed in vacuo with protection from moisture and the residue distilled to give 1. 72 
. g(37%)of19,26 bp71-74 °C (1.2 mm Hg). FT-IR v 2277 (N=C=O). 1HNMR(300MHz) 
o 6.92 (dd, 1 H, J = 5.6, 1.4 Hz, H5), 6.81 (dd, 1 H, J = 5.6, 3.7 Hz, H4), 6.68 (dd, 1 H, J = 
3.7, 1.4 Hz, H3). 13C NMR (75 MHz)<> 133.5, 125.8, 120.6, 120.4. 
N-Benzyl-N' -2-(thienyl)urea (20). Benzylamine (550 µL, 0.54 g, 5.1 mmol) was 
added dropwise to a stirred solution of 2 M2-thienylisocyanate (19 in CC14, 2.5 mL, 0.63 g, 
5.0 mmol) in carbon tetrachloride (37 mL) forming· a white precipitate on contact The 
mixture was stirred for 15 min then filtered and washed with carbon tetrachloride to isolate 
N-benzyl-N'-2-(thienyl)urea (1.10 g, 94%), mp 166-167 °C. 1H NMR (300 MHz, CDC13) 
o 7.35-7.23 (m, 5 H, Ar), 7.00 (dd, 1 H, J= 5.6, 1.4 Hz, H5), 6.86 (dd, 1 H,J= 5.6, 3.7 Hz, 
H4), 6.69 (dt, 1 H, J= 3.7, 1.4 Hz, H3), 6.49 (broads, 1 H, NH), 5.19 (broad t, l H, NH-
CH2), 4.43 (d, 2 H,J= 5.9Hz, CH2); (300MHz, acetone-d6) o 8.88 (broads, 1 H, NH), 7.35-
7.13 (m, 5 H, Ar), 6.75 (m, 2 H, H5 andH4), 6.45 (dd, 1 H,J= 3.2, 1.9 Hz, H3), 6.35 (broad 
s, 1 H, NH-CRz), 4.42 (d, 2 H,J= 6.0 Hz, CH2); (300 MHz, DMSO-d6) <> 9.52 (broads, 1 H, 
NH), 7.34-7.22 (m, 5 H, Ar), 6.75-6.67 (m, 3 H, H4, H5, and.NH-CH2), 6.14 (dd, 1 H,J= 
3.2,1.9 Hz, H3), 4.41 (d, 2 H, J= 6.0 Hz, CH2). 13C NMR (75 MHz, acetone-d6) <> 155.55, 
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143.33, 141.36, 129.32, 128"29, 127.82, 122.75, 116.42, 109.76,44.34;(75MHz,DMSO-d6) 
o 154.53, 142.21, 140.42, 128.43, 127.20, 126.87, 124.11, 115.21, 108.25, 42.95. 
2-Benzyl-1,4-dibydro-l-bydroxytbieno(3,2-c) (1,5,2]diazaborin-3(2H)-one (21 ). 
To a stirred solution of 1.0 MBC13 in xylene (1.20 mL, 0.141 g, 1.20 mmol) in 1,2-dichloro-
ethane ( 10 mL) was added via cannula over 25 minutes a solution of N-benzyl-N'-(2-
thienyl)urea (20,220 mg, 0.95 mmol) in 1,2-dichloroethane (50 mL). Aluminum chloride 
(10.0 mg, 0.08 mmol) was then added and the reaction refluxed under nitrogen. Reaction 
aliquots (100 µL) were removed, quenched with a mixture of water (500 µL), 200 mM 
sodium phosphate buffer ( 5 µL ,pH 7.5 buffer), and methanol ( 1 mL) and analyzed by HPLC 
(C18 column, 4.6 x 250 mm, 1 mLJminute, 100:0 water:acetonitrile to 65:35 
water:acetonitri1e over 35 min). After 14 d, the reaction was quenched with a mixture of 
water (20 mL) and 200 mM sodium phosphate buffer (6 mL, pH 7.5 buffer). The organic 
layer was separated, dried, filtered, and evaporated. The crude product was purified by 
preparative HPLC (C18 column, 21.4 x 250 mm, 12 mUmin, 65:35 water:acetonitrile). 
Evaporation of solvent and drying in vacuo afforded 30 mg ( 13%) of the desired product, 
mp 109-112 °C. UV (CH3CN) A max 214 run (e 34,500), A max 268 nm (e 6,500); 
( CH30H) A max 253 nm ( E 17,300), A max 265 nm ( e 19,700). MS (LR-F AB, 3-nitrobenzyl 
alcohol matrix) mlz 259 (Ml-i+), 394 (Ml-i+ + matrix -H20); (LR-FAB, glycerol matrix) mlz 
259 (Mli+), 333 (Mli+ + matrix - H20); (HR-FAB) mlz 259.0714 (Mli+) C 12H 11BN20 2S 
requires 259.07136. 1H NMR (600 MHz, acetone-d6) o 10.31 (broads, 1 H, NH), 8.42 (s, 
1 H., OH), 7.40 (apparent dm, 2 H., J = 7.6 Hz, Ar H2, H2'), 7.26 (apparent tm, 2 H., J = 7.6 
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Hz, Ar H3, H3'), 7.22 (d, 1 H, J = 5.4 Hz, H6), 7.17 (apparent tm, 1 H, J = 7.5 Hz, Ar H4), 
6.85 (d, 1 H, J = 5.4 Hz, H7), 4.87 (s, 2 H, CH2); (300 MHz, CDC13) o 8.79 (broads, 1 H, 
NH), 7.44 (apparentd,2H,J=6.9Hz,ArH2,H21, 7.34-7.22 (m, 3H,ArH3,H3',H4), 6.99 
(d,1 H, J =5.4 Hz, H6), 6.77 (d,l H, J =5.4 Hz, H7), 4.91 (s, 2 H, CH2), 4.79 (s, 1 H, OH); 
(300 MHz, acetonitrile-d3) o 9.46 (broads, 1 H, NH), 7.32-7.19 (m, 5 H, Ar), 7.15 (d, 1 H, 
J=5.5 Hz, H6), 7.01 (s, 1 H, OH), 6.81 (d, 1H,J=5.4 Hz, H7), 4.80 (s, 2 H, CH2); (400 
MHz, methanol-d4) o 7.36 (d, 1 H, J=5.4 Hz, H6), 7.35-7.14 (m, 5 H, Ar), 6.92 (d, 1 H, J 
=5.4 Hz, H7), 4.81 (s, 2 H, CH2); 13CNMR (75 MHz. acetone-d6) o 1S6.4, 156.l, 141.5, 
129.0, 128.9, 128.2, 127.5, 115.~, 44.8; (75 MHz, acetonitrile-d3) o 156.5, 156.2, 141.3, 
129.4, 128.4, 128.3, 127.8, 116.2, 45.0; 11B NMR (128 MHz, acetone-d6) o 33.5 (v112 = 238 
Hz); (128 MHz, acetonitrile-d3) o 33.7 (v 112 = 275 Hz); (128 MHz, methanol-d4) o 32.3. 
Anal. Calcd. for C12H11BN20 2S: C, 55.84; H, 4.30; N, 10.85. Found: C, 56.12; H, 4.63; N, 
10.66. 
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CHAPTER4 
STUDIES TOW ARD 4-BORAURACIL 
Washington State University · 
With the prospect of treating cancer or HIV using boron neutron capture therapy, the 
search for stable boron-containing compounds continues. Focus has been placed on 
biological building blocks with a great deal of consideration being given to the components 
ofDNA and RNA The work presented within this chapter describes ongoing studies toward 
the synthesis of 4-borauracil, one of the many avenues for investigating potential boron 
neutron capture agents. 
The explored avenue incorporates the concept of asymmetric synthesis using boronic 
esters to direct the insertion of a CHCl group into a boron-carbon bond. This type of 
synthesis has been under investigation since before 19801,2 and continues to be a promising 
route to many boron-containing molecules. During these investigations, the methods for 
inserting the a-halo group have relied on the use oforganolithium reagents along with zinc 
chloride as a catalyst and chloride ion scavenger.3 In situ generation of the common 
organolithium reagent, (dichloromethyl)lithium from dichloromethane and butyllithium at 
-100 °C or lithium diisopropylamine at temperatures up to-20 °C.4 
This process of "homologation" or "chain extension" has been analyzed and a 
mechanism of action proposed to explain the migration of the alkyl group from the boron 
and the catalytic involvement of the zinc chloride. The mechanism does not involve any sort 
of enantioface selection, as is the case in most asymmetric syntheses. The initial 
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establishment of the asymmetric center involves selective displacement of one of the two 
diastereotopic halides during rearrangement. 3 
The sequential double diastereoselection seen with boronic esters of C2-symmetry 
depends in the inversion of the carbon atom when the alkyl group migrates to displace one 
chloride ion from the dimethylborate complex 22 to form the ( a-chloroalkyl)boronic ester 
23. Inversion places the remaining chloride of 23 in the vulnerable position for 
displacement in the subsequent borate complex 24. The C 2-symmetry makes both faces of 
the boron atom equivalent in l;>ornic ester intermediates such as 23. This is not the case with 
pinanediol esters .. which show a nonequivalence at the boron in such intermediates. 
Figure 24. Alkyl Group Migration in the Dimethylborate Complex 22. 
Cl 
H,~ R3 
R1 9-:.0-,, 
, ~o-' 3 R2 R 
24 
The strong effect of zinc chloride in promoting and directing the migration of R 1 in 
anion 22 suggests that the zinc cation might complex with one of the boronic ester oxygens 
while assisting the chloride ion to depart. A comparison of two drawings of the transition 
state, 26 and 28, was presented by Matteson to explain the observed products. 5 These 
tentative illustrations of the transition state led Corey and coworkers to write a more 
reasonable structure, 25, based on some analogies and qualitative arguments;6 
Independently, Midland carried out a set of Gaussian calculations in which he discovered 
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that Corey's proposed structure gave a lower transition state energy than the three other 
possible structures. 7 
Figure 25. Effect on Zinc Chloride on Migration of the Alkyl Group (R1). 
26 
These drawings may exaggerate the extent to which the five-membered 1,3,2-
dioxaborolane ( diol boronic ester) ring flexes so that the R3 groups are pseudoaxial (25, 27) 
or pseudoequatorial (26, 28), but in any event the ring is not planar and eclipsing strain 
between R3 and Hon the adjacent carbon is avoided. 1,3,2-Dioxaborolanes containing 
trigonal boron (e.g. 23) do have very nearly planar rings in spite of the eclipsing strain, . 
presumably as a result of strong B-0 1t-bonding,8 but even weak coordination ofa fourth 
ligand to the boron atom is enough to make the ring nonplanar. 9 
Insertion of ex-halo groups in these boronic esters allows for the introduction of other 
functional groups by substitution of the halide using standard methods. The functional 
groups that have been successfully incorporated include azido, alkoxy,10 acyloxy,11 alkyl,10 
bis( trimethylsilyl)amino, 12 cx-tributylstannyl ethers, 13 and thiols. 3 In the instances examined 
to date, the boronic esters are stable under the variety of conditions necessary for these 
substitutions to occur. The chain extension and substitution work best with nonpolar 
substituents. Much effort has been expended in attempts to incorporate common functional 
substituents into substrates for the boronic ester chain extension. The pattern that has 
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emerged is that substituents of relatively low polarity work best. After hydrocarbons, ethers 
are the most compatible substrate. Highly polar functions such asN, N-dialkylarnides appear 
to be incompatible with the chain extension reaction. 3 
Results and Discussion 
Chiral Directors 
Three very different types of boronic esters were used in the work presented here. 
Initially, the idea of using asymmetric synthesis to form the desired basic ring structure of 
the nucleobase was investigated using pinanediol and (S, S)-1,2-dicyclohexyl-l ,2-ethanediol 
("S,S-DICHED") .to protect the boronic acid and to direct the stereochemistry within the 
growing chain. The use of these chiral directors proved to be expensive and wmecessary .due 
to· the racemization of the a-carbon during acetoxy substitution. As a result, the boronic 
esters were prepared with less expensive pinacol. However, the preparation and stereo-
directing properties of pinanediol and DICHED are worth noting. 
Asymmetric (S)-pinanediol (Scheme 8, 29) prepared from ( + )-a-pinene by osmium 
tetraoxide catalyzed oxidation with trimethylamine N-oxide was introduced by Matteson and 
Ray in 1980 as an alternative to the published preparation using N-methylmorpholine N-
oxide from 1976.5 Pinanediol still remains a useful chiral director, even though its 
stereocontrol is not as precise as that of DICHED or other diols of Cz""symmetry. Once 
formed, pinanediol botonic esters are extremely resistant to hydrolysis allowing reactions 
to take place along the growing chain without loss of the ester. When treated with hydrogen 
peroxide, peroxidic deboronation occurs leaving the boronic ester. completely intact· and 
oxidizing the a-carbon in the process. 3 
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Scheme 8. Preparation of Pinanediol from ( + )-a-Pinene. 
Me3NO, Os04 HO~_.,,.. . 
t-BuOH, 70 °C · HO · 
I 
29 
DICHED (Scheme 9, 32), introduced by Hoffmann and coworkers,14 is a chiral 
director of C2-symmetry. It can be obtained in large quantities by a four-step synthesis 
starting from trans-stilbene. Sharpless dihydroxylation using osmium tetraoxide in the 
presence ofNMO and (DHQD)zPHAL gives (R)- or (S)-(R* ,R*)-1,2-diphenylethane-l ,2-diol 
(30). 15 Diol 30 is then converted to a borate ester 31 before hydrogenation over rhodium 
trichloride and alumina, generating a highly active catalyst in situ when hydrogen is 
introduced. Rhodium can then be recycled as the trichloride. The borate ester is finally 
hydrolyzed to DICHED (32).16 
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Scheme 9. Preparation ofDICHED from trans-Stilbene via Sharpless Oxidation. 
31 
Synthetic Investigations 
Os04,NMO 
(DHQD)iPHAL 
B(OCH3}3 
30 
32 
Investigations into the preparation of an acyclic precursor to the desired nucleobase 
began with the preparation of diisopropyl bromomethyl boronate (33) from triisopropyl 
borate (Scheme 10). Once the initial boronic ester 33 was prepared, the ester protecting 
group could be exchanged to provide better stereocontrol. In the case of the {S,S)-DICHED 
ester, 33 must first be converted to the pinacol ester 34. This conversion allows for a rapid 
exchange withDICHED resulting in the formation of a more stable ester of C2-symmetry 35. 
In addition to added stability, exchanging the pinacol group with DICHED increases the 
molecular mass of the ester. Stable, high molecular weight compounds are desired when 
working with azido compounds to reduce the likelihood of creating explosive materials. 
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Scheme 10. Synthetic Studies Involving DICHED Boronates. 
CH;zBr2 + B(OCH(C~)2)3 1. -78°, THF 
n-Buli 
2. CH3S03H 
o-rc: 
ar\~ 
~o 
HO OH 
Et:z() 
34 
33 
35 
NaN3 (aq) 
----
(C4H9)4N8r 
EtOAc 
. n CH;zCl2, THF n 
r,{X.0::- _z_n;,_~u-~-i ----- N,)-e~::(Q::-
36 
NaOAc, HOAc 
.. 
~ 48 hrs 
-1000-- room temp 
37 
38 
Synthesis of the azidomethyl boronic ester 36 was accomplished by a phase transfer 
reaction with sodium azide prior to homologation to insert a CHCI group next to the boron 
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atom. 5 This insertion is highly stereospecific resulting in the isolation of almost entirely the 
S-enantiomer of 37. 
Substitution of the newly introduced Cl using sodium acetate in acetic acid results 
in the racemization of the a-carbon (38) indicating that DICHED is not a reasonable choice 
for this synthetic method. However, the desired product does not necessarily need to be 
enantiomerically pure, as the final step in the proposed synthesis is the elimination of the 
acetoxy group to form a double bond within the ring of the nucleobase (Figure 26). 
Figure 26. Proposed Synthetic Pathway to 4-Borauracil. 
Upon realizing that the use of DICHED would not result in selective substitution, 
investigations were continued using S-pinanediol as the stereodirector with the idea that the 
asymmetric nature of the pinanediol might promote formation of one enantiomer over the 
other in the acetoxy substitution. Preparation of 41 (Scheme 11) is analogous to the 
previously described synthesis of 37. However, the synthesis of(S}-pinanediol 1-acetoxy-2-
azidoethyl boronate was not carried out due to the lack of stereoselectivity in the formation 
of a-chloroboronic ester 41. At this point, it was decided that asymmetric synthesis was 
neither necessary nor advantageous for the pursuit of the desired nucleobase. 
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Scheme 11. Synthetic Studies Involving Pinanediol Boronates. 
39 
1. -78°, THF 
n-Buli 
2. CH3S03H 
NaN3 (aq) 
(C4H9)4N8r 
EtOAc 
33 
40 
-100°--- room temp 
41 
In addition, synthetic complications arose during attempts to reduce the azido group 
to the corresponding amine. With the azido group in either the«- or P-position, the typically 
uncomplicated reduction causes the decomposition of the «- and P-azido boronic esters. In 
the case of the 1-acetoxy-2-azidoboronic esters 37 and 41, the decomposition appears to 
proceed by loss of the acetoxy group in addition to disruption of the ester. 
Due to the results of the attempted reductions, the question arose as to whether the 
azide could possibly be reduced in the presence of a boronic ester. An investigation into the 
effect of the azide position on the likelihood of the reduction being successful began with 
the preparation of phenethylboronic acid ( 42) as a means of introducing an internal azide 
rather than a terminal azide as seen before (Scheme 12). The other reason for incorporating 
the longer chain was to aid in the identification and stabilization of decomposition products 
if reduction of the azide were to cause the dissociation of the azido-portion of the molecule 
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from the boronic ester. In the earlier cases, the azide portion of the molecule was never 
isolated or identified. 
Scheme 12. Synthetic Studies Based on Pinacol Boronates. .· 
B(OCH3h + -----. U MgCJ 1. Et20 
43 
45 
47 
2. aqHCI 
42 
CH2Cl2, THF ~ 
n-BuLi, ZnCl2 ~I . 9 . 
~ B 
-100°- room temp . 'O 
CH2Cl2, THF 
n-BuLi, ZnCl2 
-100° ..... room temp 
44 
Cl 
46 
NaN3 (aq) 
Bu4NBr(aq) 
EtOAc 
NaOAc 
HO Ac 
Protection of the boronic acid was achieved using pinacolas opposed to the more 
expensive chiral directors, (S,S),-DICHED and (S)-pinanediol, for the purpose of 
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investigating the azide reduction. The pinacol ester 43 was then subjected to homologation 
resulting in formation of the a-chloroboronic ester 44. Azide substitution followed by a 
second homologation gave the (3-azido-a-chloroboronic ester 46. For the investigation to 
be complete, 46 had to be converted to the a-acetoxy compound 47. Preparation of this 
series of compounds allowed additional studies on a- and (3-azido reduction. Once again, 
reduction using catalytic hydrogenation, sodium borohydride, or sodium cyanoborohydride 
gave decomposition of the pinacol boronic esters (45, 46, and 47). 
Boron-11 NMR Studies of Compounds 42-47 
Boron-11 NMR data for the pinacol boronates ( 42 ~ 47) were recorded in a variety 
of solvents to confirm the proposed structures. Specifically of interest was the ability of the 
boron to remain· trigonal planar when exposed to various conditions. Boron-11 NMR 
spectroscopy has been used as a sensitive. probe of hybridization. The chemical shifts of 
approximately 33 ppm using the boron trifluoride·etherate scale are indicative of a trigonal 
.boron atom. 
Only one set of conditions shows evidence for tetrahedral boron in the 11B NMR 
spectra (a signal of approximately 20-30 ppm upfield). As expected, reaction of 
phenethylboronic acid ( 42) with NaOH led to the observation of a signal at 4.3 ppm. The 
fact that no other tetrahedral signal was observed is encouraging for the future of these 
synthetic methods; in that the acetoxy, azido, and chloro substituents appear to have little 
or no effect on the stability of the boron atom. 
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Table 4. Chemical Shifts and Peak Widths of 11B Signals for Compounds 42-47 
118 Chemical Shift tri-or 
Compound Solvent {ppm) Vuz {Hz) tetracoordinate 
42 chloroform-cf 31.80 139.4 Tricoordinate 
chloroform-d + NaOH 31.60 301.5 Tricoordinate 
4.31 545.2 T etracoordinate 
acetone-d0 32.46 149.9 Tricoordinate 
acetonitrile-d3 32.35 113.9 Tricoordinate 
methanol-d4 31.57 97.2 Tricoordinate 
0 
deuterium oxide 32.16 339.4 Tricoordinate 
43 chloroform-d 33.14 237.3 Tricoordinate 
chloroform-d + NaOH 33.09 237.2 Tricoordinate 
acetone-d0 33.97 117.5 Tricoordinate 
acetonitrile-d3 32.35 116.8 Tricoordinate 
methanol-d4 33.82 163.1 Tricoordinate 
44 chloroform-d 30.66 260.9 Tricoordinate 
chloroform-d + NaOH 29.76 Tricoordinate 
acetone-d6 31.31 136.8 Tricoordinate 
acetonitrile-d3 31.15 150.2 Tricoordinate 
methanol-d4 31.21 181.0 Tricoordinate 
45 chloroform-d 31.37 380.8 Tricoordinate 
chloroform-ct + NaOH 31.44 Tricoordinate 
acetone-d6 32.03 156.6 Tricoordinate 
acetonitrile-d3 31.86 117.3 Tricoordinate 
methanol-d4 31.80 220.9 Tricoordinate 
46 chloroform-ct 31.11 335.0 Tricoordinate 
chloroform-ct + NaOH 30.53 348.5 Tricoordinate 
acetone-d6 30.25 273.6 Tricoordinate 
acetonitrile-d3 30.97 314.4 Tricoordinate 
methanol-d4 31.17 Tricoordinate 
47 chloroform-ct 33.02 238.0 Tricoordinate 
acetone-d6 34.00 141.8 Tricoordinate 
acetonitrile-d3 33.64 154.3 Tricoordinate 
methanol-d4 33.72 183.4 Tricoordinate 
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Conclusions 
Though obstacles were encountered in the reduction of the P-azido boronic ester, 
research continues to probe the use of asymmetric synthesis as a means of constructing 
acyclic precursors to boron-containing heterocycles. Current investigations are exploring 
other methods of introducing the desired ~-amino group in addition to searching for 
conditions to accomplish the azide reduction attempted in these studies. 
Fortunately, the 11B NMR research gave one piece of valuable information about the 
stability of these compounds. Once synthesized, the boronic esters are stable in the presence 
of strong aqueous bases. This knowledge reduces the concern of possible side reactions 
resulting in the loss of the boron entity and allows consideration of other reactions along the 
growing chain. 
Experimental 
General Synthetic Procedures. NMR spectra were obtained on Mercury 300 or 
Unity Inova 400 or 600 MHz spectrometers from Varian. The 1H and 13C NMR spectra were 
recorded in CDC13, unless otherwise stated, and referenced to either internal TMS or to the 
central line of the residual solvent multiplet. Infrared spectra were obtained using a System 
2000 FT-IR instrument from Perkin-Elmer. Low and high resolution electron-impact (LR-EI 
and HR-EI) mass spectra were performed by the Washington State University Mass 
Spectrometry Lab. Elemental analyses were performed by Desert Analytics, Tucson, AZ. 
Melting points were determined on aMelTemp apparatus and are uncorrected. All reactions 
were run under an inert atmosphere of argon or nitrogen using glassware dried at l00°C. 
Tetrahydrofuran was dried over benzophenone ketyl. Unless otherwise noted, reactions are 
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dried over NazS04 followed by filtration through glass wool. Solutions were evaporated in 
vacuo using a rotary evaporator at 30°C and 20 mm Hg (water aspirator). Drying in vacuo 
refers to removal ofresidual solvent using an oil pump (<0.1 mm Hg) at room temperature. 
Thin-layer chromatography was accomplished using Whatman ™ Flexible-Backed adsorption 
plates with aluminum backing with detection using either ultraviolet light (254 run) or eerie 
ammonium sulfate stain. 17 Purification was accomplished by column chromatography18 on 
silica using combinations of pentane, ether, and hexanes as the main solvents. Chemicals 
were purchased from Aldrich and solvents from Fisher Scientific unless otherwise stated. 
Diisopropyl Bromomethyl Boronate (33). A 1-L 3-necked round-bottomed flask 
equipped with a stirring mechanism (stir bar for small scale, mechanical stirrer for large 
scale), an Ar line and a septum was placed in an ambient temperature acetone or ethanol 
bath. THF (375 mL), triisopropyl borate (58 mL, 47 g, 251 mmol), anddibromomethane (23 
mL, 57 g, 303 mmol) were added to the flask and the bath cooled to-78 °C. The septum 
was then replaced by an addition funnel. n-Butyllithium (l.6 Min hexanes, 138 mL, 301 
mmol) was added slowly over 2.5 h via the addition funnel. After the addition, the reaction 
was allowed to stir for 10 min then methanesulfonic acid (17 mL, 25 g, 262 mmol) was 
added over l O min. The reaction mixture was allowed to warm slowly to room temperature 
overnight. The THF was distilled off at atmospheric pressure using an oil bath (small scale) 
or steam bath (large scale). After the THF was removed, the flask was cooled, the 
mechanical stirrer was replaced by a stopper, and vacuum distillation of the mixture 
continued at room temperature to remove any remaining traces of solvent. The receiving 
flask was cooled to -78 °C and the distillation temperature raised to 90-100 °C until 
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distillation stopped. Additional purification was accomplished using fractional vacuum 
distillation to obtain 26. 8 g ( 48%) of diisopropyl bromomethyl boronate as a clear, colorless 
liquid, bp 51 °C at 8 mm Hg. Caution: Diisopropyl bromomethyl boronate is a 
lachrymator. MS (HR-EI) m/z 272.0580 (M·+) C11H1sBBr02 requires 272.0583. 1H NMR 
o 4.45 (septet, 2 H, J = 6.1 Hz, CH), 2.54 (s, 2 H, CH2Br), 1.20 (d, 12 H, J = 6.1 Hz, CH3). 
13C NMR o 66.5, 24.68. The carbon attached to the boron was not observed. 
· Pinacol Bromomethyl Boronate (34). A solution of pinacol (55 g, 47 mmol)in 
ether (50 mL) was .added via cannula to a mund-bottomed flask containing diisopropyl 
bromomethyl boronate (33, 103 g, 46.2 mmol) and the reaction was stirred at room 
temperature for 24 h. Evaporation of the solvent yielded a crude mixture of products which 
was distilled to yield 91.8 g (90%) ofdiisopropyl bromomethyl boronate, bp 35 °Cat 0.3 
mm Hg. 1HNMR o 2.59 (s, 2 H, BrCH2), 1.29 (s, 12 H, <;H3). 13C NMR o 84.72, 24.88. 
(S,s)-1,2-Dicyclohexyl-1,2-ethanediol Bromomethyl Boronate (35), (S,S)-
DICHED (9.20 g, 40.6 mmol) was added to a round-bottomed flask containing pinacol 
bromomethyl boronate (34, 9.13 g, 41.3 mmol) in ether (75 mL) and the reaction was stirred 
at room temperature for 24 h. The resulting organic phase was extracted with H20 (2 x 20 
mL), dried, and filtered. Evaporation of the solvent yielded a crude mixture of products 
which was distilled at less than 1 mm Hg. All impurities were removed below 100°C. 
Distillation afforded 9 .24 g ( 68%) of pure (S,S)-DICHED bromomethyl boronate. 1H NMR 
o 3.96 (apparent d, 2 H, 0-CH), 2.62 (s, 2 H, CH2Br), 1.83-0.90 (m, 20H, ring H's). 13C 
NMR o 84.55, 43.17, 33.69, 28.57, 27.59, 26.75, 26.62, 26.52, 26.34, 26.19. 
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(S,s)-1,2-Dicyclohexyl-l,2-ethanediol Azidomethyl Boronate (36). (S,8)-DICHED · 
bromomethyl boronate (35, 9.23 g, 28.0 mmol) was dissolved in ethyl acetate (10 mL). 
Aqueous sodium azide (24.9 g, 383 mmol) in 50 mL H20 and tetrabutylammonium bromide 
(1.87 g, 5.80 mmol) in 10 mL H20 were then added to the stirred boronic ester solution and 
the reaction stirred under Ar for 24 h. The layers were then separated and the aqueous layer 
extracted with ether (2 x 20 mL ). The combined organic layers were evaporated to yield 8.3 
g (102%) of (S,8)-1,2-dicyclohexyl-1,2-ethanediol azidomethyl boronate as a pale yellow 
syrup. 
(S, S)-1,2-Dicyclohexyl-l,2-ethanediol 2-Azido-l-chloroethyl Boronate (37). To 
a 1-L, 3-necked round-bottomed flask equipped with a mechanical stirrer, a septum, and an 
Ar inlet was added THF (170 mL) and CH2Cl2 (6.8 mL, 9.0 g, 106 mmoi). The flask was 
cooled to-100 °C using ethanol, dry ice, and liquid N2_. To the cooled THF/CH2Cl2 solution 
was added 1.6 M n-butyllithium in hexanes (35 mL, 3.6 g, 56 mmol) slowly down the walls 
of the flask. The flask was rinsed with THF ( 5 mL) and allowed to stir at -100 ° C for 30 
min. [Note: If the solution turns black during this 30 min period, do not proceed. The 
resulting solution should be colorless to pale yellow at the end of the 30 min.] A solution 
of (S$)-l,2-dicyclohexyl-1,2-ethanediol azidomethyl boronate (36, 8.15 g, 28.0 mmol) in 
THF (15 mL) was then added via syringe directly to the stirred solution while avoiding the 
walls of the flask. The mixture was stirred for an additional 30 min at -100 °C. A 1.0 M 
solution of ZnC12 in ether (65 mL, 8.9 g, 65 mmol) was then added over 10 min using a 
dropping funnel and the mixture was allowed to warm slowly overnight to room 
temperature. Ether (100 mL) was added to the flask and the solution washed with 50% 
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aqueous NH.iCl (2 x 35 mL ). The organic layer was separated, dried, and evaporated to yield 
9. 09 g (96%) of (S)',')-1,2-dicyclohexyl- l ,2-ethanediol 2-azido-1-chloroethyl boronate as a 
pale yellow syrup. 1HNMR.o 3.98 (d, 2 H, 0-CH), 3.72-3.55 (m, 3 H, CH2-N3 and CH-Cl), 
1.90-0.80 (m, 20 H, cyclohexyl). 13C NMR o 84.5, 54.6, 42.8, 28.2, 27.2, 26.4, 26.0, 25.9. 
(S,s)-1,2-Dicyc1ohexyl-1,2-ethanediol 1-Acetoxy-2-azidoethyl Boronate (38). S,S-
DICHED 1-cbloro-2-azidoethyl boronate (37, 1.00 g, 2.94 mmol), sodium acetate{242 mg, 
2.94 mmol) and acetic acid (2.8 mL) were combined in a reflux apparatus and heated at 
75°C for 48 h. The acetic.acid was evaporated and the resulting syrup purified by silica gel 
chromatography (pentane-+ether gradient)to yield 228 mg (22%) of (S,S)-1,2-dicyclohexyl-
1,2-ethanediol l-acetoxy-2-azidoethyl boronate. FT-IR v 2099 (N3), 1734 (C=O). 1H NMR 
o 4.34 (ddd, 1 H, CH-OAc), 3.89 (apparent. t, 2H, 0-CH), 3.65-3.48 (m, 2H, CH2N3), 2.13 
(s, 3 H, CH3), 1.83-0.85 (m, 20 H, cyclochexyl). 13C NMR o 172.7, 84.5, 52.1, 43.0, 28.8, 
27.8, 26.8, 26.3, 26.2, 20.6. 
(S)-Pinanediol Bromomethyl Boronate (39). A solution of (~')-pinanediol (4.08 g, 
24.0 mmol) in ether (25 mL) was added via cannula to a round-bottomed flask containing 
diisopropyl bromomethyl boronate (33, 5.26 g, 23.6 mmol) and the reaction was stirred at 
room temperature for 2 h. Evaporation of the solvent yielded a crude mixture of products 
which was chromatographed on silica gel (30:1 pentane:ether). Pure (S)-pinanediol 
bromomethyl boronate was recovered in 89% yield as a clear syrup, Rr 020 (30:1 
pentane:ether). MS (HR-EI) mlz 272.0580 (M+) C 11H13BBr02 requires 272.0583. 1H NMR 
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o 4.38 (dd, 1 H,J= 8.8, 1.9 Hz, OCH), 2.64 (s, 2 H, CH2Br), 2.40-2.22 (m, 2 H, ringH), 2.09 
(apparent t, 1 H, ring H), 1.96-1.87 (m, 2 H, ring H), 1.42 (s, 3 H, CH3), 1.30 (s, 3 H, CH3), 
1.20 (d, 1 H, J = 11.2 Hz, CH), 0.85 (s, 3 H, CH3). 
(S)-Pinanediol Azidomethyl Boronate ( 40). (S)-Pinanediol bromomethyl boronate 
(39, 2.99 g, 11.0 mmol) was dissolved in ethyl acetate (40 mL). Aqueous sodium azide (25 
g, 385 mmol) in 85 mL H20 and tetrabutylammonium bromide (1.77 g, 5.49 mmol) in 25 
rrJL H20 were then added to the stirred boronic ester solution and the reaction was stirred 
under Ar for 5 d. The layers were then separated and the aqueous layer extracted with ether 
(2 x 20 mL ). The combined organic layers were evaporated to yield 2.2 g (84%) of (S)-
pinanediol azidomethyl boronate as a pale yellow syrup. 1H NMR o 4.36 (dd, 1 H, J = 8.8, 
1.9 Hz, OCH), 3.10 (s, 2 H, CH2N3), 2.39-2.22 (m, 2 H, ring H), 2.08 (dt, 1 H, J = 4.5, 3.0 
Hz, ring H), 1.96-1.92 (m, 1 H, ring H), 1.88 (dd, 1 H, J = 3.3, 1.9 Hz, CH), 1.43 (s, 3 H, 
CH3), 1.30 (s, 3 H, CH3), 1.13 (d, 1 H,J= 11.2 Hz, CH), 0.85 (s, 3 H, CH3). 13C NMR o 
87.0, 78.7, 51.3, 39.7, 38.4, 35.4, 28.8, 27.3, 26.8, 24.3. 
(S)-Pinanediol 2-Azido-1-chloroetbyl Boronate (41). To a 1-L, 3-necked round-
bottomed flask equipped with a mechanical stirrer, a septum, and an Ar inlet was added THF 
(60 mL) and CH2Cl2 (2.5 mL, 3.3 g, 39 mmol). The flask was cooled to -100 °C using 
ethanol, dry ice, and liquid N 2 .• To the cooled THF/CH2Cl2 solution was added 1.6 Mn-
butyllithium in hexanes (13.3 mL, 1.36 g, 21.3 mmol) slowly down the walls of the flask. 
The flask was rinsed with THF (5 mL) and allowed to stir at -100 ° C for 30 min. [Note: If 
the solution turns black during this 30 min period, do not proceed. The resulting solution 
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should be colorless to pale yellow at the end of the 30 min.] A solution of (S)-pinanediol 
azidomethyl boronate (40, 2.5 g, 10.6 mmol) in THF (8 mL) was then added via syringe 
directly to the stirred solution while avoiding the walls of the flask. The mixture was stirred 
for an additional 30 min at-100 °C. A 1.0 Msolution of ZnC12 in ether (21.2 mL, 2.98 g, 
21 ;2 mmol) was then added over 10 min using a dropping funnel and the mixture was 
allowed to warm slowly overnight to room temperature. Ether ( 40 mL) was added to the 
flask and the solution washed with 50% aqueous NH4Cl (2 x 20 mL ). The organic layer was 
separated, dried, and evaporated to yield 3.9 g (130%) of (S)-pinanediol '2-azido-1-
chloroethyl boronate. 
Phenethylboronic Acid (42). To a 1-L, 3-necked round-bottomed flask equipped 
with a mechanical stirrer, an Ar inlet, and a septum was added ether (300 mL). The flask 
was cooled to -78 °C before trimethyl borate (35 mL, 32 g, 308 mmol) was added via 
syringe. The mixture was stirred and the septum replaced by an addition funnel. A 1.0 M 
solution of phenethylmagnesium chloride in THF (300 mL, 300 mm~l) was introduced via 
syringe into the addition funnel and slowly added to the reaction flask over 45 min. The 
reaction was allowed to stir for 30 min then warmed to room temperature. The reaction 
mixture was poured over 300 mL of ice and acidified with 2 MHCl (200 mL) then poured 
back into the reaction vessel to dissolve the solid which had clumped in the flask. The 
biphasic solution was separated and the aqueous layer extracted with ether (2 x 200 mL ). 
The combined ether extracts were washed with water ( l 00 mL) and saturated NH4Cl (l 00 
mL) then dried and evaporated. The crude product was used directly in the synthesis of 74. 
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1HNMR o 7.35-7.15 (m, 5 H, Ph), 5.75 (br s, 2 H, OH), 2.75 (t, 2 H,J= 8.2 Hz, CHrPh), 
l.15(t,2H, J=8.2Hz,CH2-B). 13CNMRo 144.1, 128.2, 127.7, 125.5,30.23. 
Pinacol 2-Phenethyl Boronate (43). A solution of pinacol (36.4 g, 308 mmol) in 
ether (125 mL) was added to a solution of phenethylboronic acid (42, 45.0 g, 300 mmol) in 
ether (125 mL) and the reaction stirred at room temperature for 30 min. An additional 
portion of ether ( 100 mL) was added and the solution washed with water (2 x 50 mL) 
followed by saturated NH4Cl (50 mL). The ether layer was dried and evaporated. Simple 
distillation of the crude product served to purify 51.5 g (71.4% based on 
phenethylmagnesium chloride) of pinacol 2-phenethyl boronate, bp 110 ° C at <l mm Hg. 
1HNMR o 7.30-7.12 (m, 5 H, Ar), 2.75 (t, 2 H,J= 8.2 Hz, CH2Ph), 1.22 (s, 12 H, CH3), 1.15 
(t, 2 H, J = 8.2 Hz, CH2B). 13C NMR o 144.2, 128.1, 127.9, 125.4, 83.1, 30.0, 24.9. 
Pinacol 1-Cbloro-3-Phenylpropyl Boronate (44). To a 1-L, 3-necked round-
bottomed flask equipped with a mechanical stirrer, a septum, and an Ar inlet was added THF 
(500 mL) and CH2Cl2 (29 mL, 38 g, 452 mmol). The flask was cooled to -100 °C using 
ethanol, dry ice, and liquid N2_. To the cooled THF/CH2Cl2 solution was added 1.6 M n-
butyllithium in hexanes (88 mL, 9.0 g, 141 mmol) slowly down the walls of the flask. The 
flask was rinsed with THF (5 mL) and allowed to stir at-100 °C for 30 min. [Note: If the 
solution turns black during this 30 min period, do not proceed. The resulting solution should 
be colorless to pale yellow at the end of the 30 min.] A solution of pinacol 2-phenethyl 
boronate (43, 27.04 g, 116.5 mmol) in THF (5 mL) was then added via syringe directly to 
the stirred solution while avoiding the walls of the flask. The mixture was stirred for an 
90 
additional 30 min at -100 °C. A 1.0 M solution of ZnC12 in ether (235 mL, 32.0 g, 235 
mmol) was then added over 10 min using a dropping funnel and the mixture was allowed 
to warm slowly overnight to room temperature. Ether ( 150 mL) was added to the flask and 
the solution washed with 50% aqueous ~Cl (150 mL). The organic layer was separated, 
dried, and evaporated to yield 38.6 g (118%) of l-chloro-3-phenylpropyl pinacolboronate 
as an orange-brown syrup. 1H NMR o 7.33-7.18 (m, 5 H, Ar), 3.43 (t, 1 H, J = 7.4 Hz, 
CH2Cl), 2.82 (ddt, 2 H, J = 7.4, 7.1, 6.2 Hz, CH2Ph), 2.13 (dt, 2 H, J= 7.4, 7.1 Hz, CH2), 
1.30 (s, 12 H, CH3). 13CNMR o 140.9, 128.5, 128.3, 125.9, 84A, 35.7, 33.3, 24.8. 
Pinacol 1-Azido-3-phenylpropyl Boronate (45). To a stirred solution of pinacol 
l-chloro-3-phenylpropyl boronate (44, 38.57 g, 137.5 mmol) in EtOAc (30 mL) was added 
aqueous sodium azide (36.17 g, 556.3 mmol) in 90 mL H20 and aqueous 
tetrabutylammonium bromide (7.02 g, 21.8 mmol) in 10 mLH20. The reaction mixture was 
heated at 75°C for 18 h protected by Ar and a reflux condenser. The reaction was cooled 
to room temperature and the phases separated. The aqueous phase was washed with ether 
(15 mL). The combined organic phases were then washed with saturated NH4Cl (25 m.L), 
separated, dried, and evaporated. The crude syrup was purified using silica gel 
chromatography (pentane .... ether gradient) to give 19.7 g (59%) of pinacol l-azido-3-
phenylpropyl boronate from pinacol phenethyl boronate. FT-IR v 2095 (N3). 1H NMR o 
7.32-7.17 (m, 5 H, Ar), 3.11 (t, 1 H,J = 7.2 Hz, CH2N3), 2.82-2.71 (m, 2 H, CH2Ph), 1.97 (dt, 
2 H, J= 7.7, 7.2 Hz, CH2), 1.28 (s, 12 H, CH3). 13C NMR B 141.1, 128.5, 128.4, 128.3, 
125.9, 84.5, 33.4, 32.5, 24,9, 24.8. 
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Pinacol 2-Azido-l-chloro-4-phenylbutyl Boronate ( 46). To a 1-L, 3-necked round-
bottomed flask equipped with a mechanical stirrer, a septum, and an Ar inlet was added THF 
(500 mL) and CH2Cl2 (20 mL, 26 g, 312 mmol). The flask was cooled to -100 °C using 
ethanol, dry ice, and liquid N2• To the cooled THF/CH2Cl2 solution was added 1.6 Mn-
butyllithium in hexanes (60 m_L, 6.1 g, 96 mmol) slowly down the walls of the flask. The 
flask was rinsed with THF (5 rnL) and allowed to stir at -100 °C for 30 min. [Note: lfthe 
solution turns black during this 30 min period, do not proceed. The resulting solution should 
be colorless to pale yellow at the end of the 30 min.] A solution of pinacol 1 .,azido-3-
phenylpropyl boronate (45, 23.18 g, 80.72 mmol) in THF (5 mL) was then added via syringe 
directly to the stirred solution while avoiding the walls of the flask. The mixture was stirred 
for an additional 30 min at-100°C. A 1.0 M solution of ZnC12 in ether (165 rnL, 22.5 g, 165 
• 
mmol) was then added over 10 min using a dropping funnel and the mixture was allowed 
to warm slowly overnight to room temperature. Ether (150 rnL) was added to the t1ask and 
the solution washed with 50% aqueous NH4Cl (150 mL). The organic layer was separated, 
dried, and evaporated to obtain 34.8 g (129%) of pinacol 2-azido-l-chloro-4-phenylbutyl 
boronate. FT-IR v 2102(N3). 1HNMRo7.4-7.2(m,5H,Ph),5.3(s,2H,O-CH),3.7-3.6 
(m, 1 H, CH-Cl), 3.5 (dd, 2 H, CH2-Ph), 2.9-2.6 (m, 2 H, CHz-N3), 2.0 (s, 2 H, CH2), 1.1 (s, 
Pinacol 1-Acetoxy-2-azido-4-pbenylbutyl Boronate (47). A mixture of pinacol 2-
azido-1-chloro-4-phenylbutyl boronate (46, 10.03 g, 29.9 mmol), sodium acetate (2.48 g, 
30.3 mmol), and acetic acid (30 mL) was heated at 75 °C for 63 h. The excess acetic acid 
was removed by simple vacuum distillation. The crude mixture was dissolved in ether and 
92 
washed with water to remove any excess salts and neutralized with NaOH After separation 
of the layers and evaporation of the ether the product was cbromatographed (pentane --. 
ether gradient) to yield 1.9 g (18%) ofpinacol 1-acetoxy-2-azido-4-phenylbutyl boronate. 
FT-IR v 2101 (N3), 1730 (C=O). MS (HR-El) m/z 359.2016 (MH+) C 18H26BN30 4 requires 
360.2054. 
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Plate I: 1H NMR of Compound 3 in chloroform-d 
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Plate II: 13C NMR of Compound 3 in chlorofonn-d 
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Plate IV: 13C Niv1R of Compound 5 in chloroform-d 
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Plate V: 1H NMR of Compound 7 in chlorofonn-d 
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Plate VI: 13C NMR of Compound 7 in chloroform~d 
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Plate VII: 1HNMRofCompound 10 inchloroform-d 
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Plate X: 1H NMR of Chloride Intennediate in Preparation of Compound 12 in 
chlorofonn-d 
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Plate XI: 13C NMR of Chloride Intermediate in Preparation of Compound 12 in 
chloroform-d 
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Plate XII: FT-JR of Compound 12 
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Plate XIII: 1H NMR of Compound 14 in chloroform-d 
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Plate XIV: COSY of Compound 14 in chloroform-d 
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Plate XV: 1H NMR of Compound 16 in chloroform-d 
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Plate XVI: FT-IR of Compound 18 
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Plate XVII: FT-IR of Compound 19 
... .,,,_ 
l -=========~===::=:==========--· ~-- .. 
l 
.__~~~---~---~---~-'--,,----~~§ 
~· ~ 
· ...• 
111 
Plate XVIII: 1H NMR of Compound 19 in chlorofonn-d 
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Plate XIX: 13C NMR of Compound 19 in chloroform-d 
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Plate XX: 1H NMR of Compound 20 in chloroform-d 
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Plate XXI: 1H NMR of Compound 20 in acetone-d6 
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Plate XXII: 1H NMR of Compound 20 in dimethyl sulfoxide-d6 
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Plate XXIII: · 13C NMR of Compound 20 in acetone-d6 
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Plate XXIV: 13C NMR of Compound 20 in dimethyl sulfoxide-d6 
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Plate XXV: 1H NMR of Compound 21 in acetone-d6 
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Plate XX.VI: 1H NMR of Compound 21 in chloroform-d 
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Plate XXVII: 1H NMR of Compound 21 in acetonitrile-d3 
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Plate XXVIII: 1H NMR of Compound 21 in methanol-d4 
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Plate XXIX: 13C NMR of Compound 21 in acetone-d6 
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Plate XXX: 13C NMR of Compound 21 in acetonitrile-d3 
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Plate XXXI: nB NMR of Compound 21 in acetone-d6 
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Plate XXXII: 11B NMR of Compound 21 in acetonitrile-d3 
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Plate XXXIII: nB NMR of Compound 21 in methailol-d4 
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Plate XXXIV: 1H NMR of Compound 33 in chloroform-d 
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Plate XXXV: 13C NMR of Compound 33 in chloroform-d 
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Plate XXXVI: 1H NMR of Compound 34 in chloroform-d 
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Plate XXXVII: 13C NMR of Compound 34 in chloroform-d 
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Plate XXXVIII: 1H NMR of Compound, 35 in chlorofonn-d 
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Plate IXL: 13C NMR of Compound 35 in chloroform-d 
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Plate XL: 1H NMR of Compound 37 in chloroform-d 
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Plate XLI: 13C of Compound 37 in chlorofonn-d 
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Plate XI.JI: FT-IR of Compound 38 
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Plate XI.JU: 1H NMR of Compound 38 in chlorofonn-d 
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Plate XLIV: 13C NMR of Compound 38 in chloroform-d 
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Plate XL V: 1H NMR of Compound 39 in chlorofonn-d 
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Plate XL VI: 1H NMR of Compound 40 in chlorofonn-d 
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Plate XL Vil: 13C NMR of Compound 40 in chlorofonn-d 
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Plate XL VIII: 1H NMR of Compound 42 in chloroform-d 
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Plate IL: 13C NMR of Compound 42 in chlorofonn-d 
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Plate L: 11B NMR Comparison of Compound 42 to Compound 42 after reaction with 
Na OH 
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Plate LI: 1H NMR of Compound 43 in chloroform-d 
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Plate LII: 13C N1\1R of Compound 43 in chloroform-d 
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Plate LIII: 1H NMR of Compound 44 in chlorofonn-d 
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Plate LIV: 13C NMR of Compound 44 in chloroform-d 
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Plate LV: COSY NMR of Compound 44 
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Plate L VI: FT-JR of Compound 45 
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Plate L VII: 1H NMR of Compound 45 in chloroform-d 
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Plate L VITI: 13C NMR of Compound 45 in chloroform-d 
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Plate LIX: FT-IR of Compound 46 
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Plate LX: 1H NMR of Compound 46 in chloroform-d 
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Plate LXI: FT-IR of Compound 47 
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